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ABSTRACT 
 
TIANA A. GARRETT:  Vascular Endothelial Growth Factor (VEGF)-regulated 
Endothelial Cell Behavior Through The Rho Family of Small GTPases 
(Under the direction of Dr. Keith Burridge) 
 
 
Vascular endothelial growth factor (VEGF) is an important signaling molecule in 
endothelial cell behavior and function during embryogenesis and the maintenance of 
adult tissues. VEGF signaling regulates nascent blood vessel formation (vasculogenesis 
and angiogenesis) by stimulating endothelial cell migration and decreased barrier 
integrity (vascular permeability) by modulating endothelial cell-cell junction 
disassembly. Dysregulated VEGF signaling has been implicated in tumor angiogenesis, 
ischemic stroke, and a number of other vascular diseases, but the pathways downstream 
of VEGF signaling remain incompletely defined.  
VEGF signals through various intracellular effectors to elicit its biological 
responses. One of these effectors, the Rho family of small GTPases, regulates many 
cellular processes that involve reorganization of the actin cytoskeleton such as migration 
and adhesion.  Rac1, one member of this family, promotes VEGF-induced endothelial 
cell migration by stimulating the formation of lamellipodia and membrane ruffles.  In 
addition, Rac1 disrupts vascular barrier integrity by mediating tyrosine phosphorylation 
of proteins at cell-cell junctions through reactive oxygen species (ROS) redox signaling.  
Like other GTPases, Rac1 works as a molecular switch that requires the exchange of 
GDP for GTP to become activated.  This activation is stimulated by guanine nucleotide 
exchange factors (GEFs). VEGF has been shown to activate Rac1 and mediate Rac1-
 iii
specific biological responses, but the GEFs downstream of VEGF that stimulate Rac1 are 
unknown. The research described in this dissertation demonstrates that Rac GEF Vav2 
couples VEGF signaling to Rac1 in a VEGFR-2- and Src-dependent manner.  This 
signaling pathway is necessary for endothelial cell migration that precedes blood vessel 
formation.  In addition, VEGF stimulates tyrosine phosphorylation of adherens junction 
proteins β-catenin and VE-cadherin in a ROS-dependent manner, which is essential for 
vascular permeability. 
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CHAPTER ONE 
 
BACKGROUND AND SIGNIFICANCE 
 
The vascular system is a network of blood vessels that maintain homeostasis 
throughout the vertebrate body. These blood vessels serve as conduits to allow the 
transport of leukocytes for immune response as well as erythrocytes and macromolecules 
for oxygen and nutrient delivery.  The inner lining of the vessel wall, the endothelium, is 
composed of a single layer of interconnecting endothelial cells.  This design allows 
endothelial cells to interact directly with circulating cells and other substances moving 
within the lumen of blood vessels.  For that reason, endothelial cells play a critical role in 
regulating vascular function during physiological and pathological processes.   
Two major processes that endothelial cells stringently regulate are blood vessel 
formation and the passage of fluid and leukocytes across the endothelium termed vascular 
permeability.  Endothelial cells mediate the formation of new blood vessels during 
embryonic development and adult tissue maintenance1,2. During embryonic development, 
nascent blood vessels are created from three origins:  mesoderm-derived precursor cells 
called angioblasts (vasculogenesis), mature pre-existing vessels (angiogenesis), or 
interstitial tissue that inserts into and divides the lumen of pre-existing vessels 
(intussusception) 2-5.  In adults, blood vessels primarily arise from angiogenic sprouting 
or intussusception to promote wound healing or facilitate biological processes such as 
menses and pregnancy1.  In all situations, the migration of endothelial cells is imperative 
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for determining the location and organizing the structure of new blood vessels.  However, 
when endothelial cell migration is temporally or spatially dysregulated, it can cause or 
exacerbate a multitude of pathologies including rheumatoid arthritis, diabetes, and tumor 
angiogenesis in cancer6.    
Endothelial cells also provide a barrier between the blood vessel lumen and 
surrounding tissues.   As a barrier, endothelial cells regulate the passage of leukocytes 
and soluble factors from the bloodstream to underlying tissues.  The disassembly of this 
barrier is facilitated by endothelial cells that are active, not passive, mediators of vascular 
permeability.  Vascular permeability involves the transient uncoupling of several 
adhesion molecules that tightly connect endothelial cell-cell junctions, the facilitated 
movement of responsive cells or other factors between junctions, and the swift resealing 
of junctions to restore barrier integrity.  While this process is important for normal 
physiology, inappropriate permeability can result in edema (the excessive leakage of 
blood from the vascular system) or aberrant immune responses leading to inflammatory 
disorders such as atherosclerosis and psoriasis7,8.    
In both cell migration and permeability, endothelial cell behavior is mediated by 
soluble and/or adhesive signals from circulating cells in the bloodstream. However, the 
signaling pathways that regulate endothelial cells during these processes remain poorly 
defined.  One molecule shown to have a strong influence on endothelial cell behavior is a 
soluble glycoprotein called vascular endothelial growth factor, or VEGF.  VEGF, which 
is secreted by several different cell types, is a strong promoter of endothelial cell 
migration during vascular development; though,  it was initially characterized as a 
permeability factor secreted from rodent tumors9-12.  Due to its initial characterization, 
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VEGF was originally termed vascular permeability factor (VPF).  Since its discovery in 
1983 by Senger et al., work from several groups have shown that VEGF is necessary for 
basic cellular processes like proliferation as well as many endothelial cell-specific 
functions including capillary sprouting and vascular remodeling9,13,14.   In addition to 
initiating blood vessel formation, VEGF modulates a series of events to promote and 
maintain a mature, functioning vasculature15.  Also, leukocytes adhere to and traverse 
endothelial cells in response to high concentrations of VEGF to decrease barrier function 
during transendothelial migration (TEM)16-18. Aberrant VEGF signaling is linked to many 
of the aforementioned pathologies suggesting that VEGF is required for endothelial cell 
function.  Understanding how VEGF signaling affects endothelial cell behavior is 
necessary for elucidating the molecular mechanisms underlying biological activities. 
Soluble VEGF is secreted by activated cells in response to numerous stimuli 
including hypoxia, low pH, and inflammatory cytokines19.  VEGF binds to the 
extracellular domain of cognate VEGF receptor tyrosine kinases on endothelial cells, 
which dimerize and transphosphorylate critical C-terminus tyrosine residues to initiate 
intracellular signaling.   This signaling cascade then activates many downstream effectors 
to confer its cellular, and ultimately, biological effects.  One of these effectors is the Rho 
family of small GTP-binding proteins. The Rho family of small GTPases is divided into 
nine subfamilies including Rho, Rac, and Cdc42.  These proteins have many functions 
within cells. One of these functions is reorganizing the actin cytoskeleton during 
processes required for cellular growth and survival such as migration, adhesion, vesicle 
trafficking, and gene expression20-22.  Although VEGF signals through many of these 
subfamilies, proteins of the Rac subfamily strongly regulate endothelial cell migration 
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and vascular permeability23,24.  As the prototype member of this family, Rac1 promotes 
migration by stimulating actin reorganization to form membrane ruffles and a sheet-like 
membrane protrusions called lamellipodia.  Specifically, VEGF acts through Rac1 to 
stimulate lamellipodia formation at the leading edge of polarized cells for directional 
migration, or chemotaxis25,26. VEGF has been shown to activate Rac1 during migratory 
events, but the upstream mediators that couple VEGF signaling to Rac1 are not fully 
defined. 
Rac1 also induces vascular permeability by facilitating the generation of free 
radicals from the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 
complex of endothelial cells.  These free radicals combined with other ions to form 
reactive oxygen species (ROS) that inactivate protein tyrosine phosphatases (PTPs), 
which in turn, regulate the phosphorylation status of adhesion proteins at endothelial cell-
cell junctions27,28.  Phosphorylation of specific adhesion proteins weakens contact with 
neighboring cells, thus causing vascular permeability through lessened barrier function.  
Previous work has showed that ROS-induced permeability depends on Rac1 activation, 
yet it remains unclear how ROS affects phosphorylation of adhesion molecules at cell-
cell junctions29,30.   
Overall, this study will examine the effects of VEGF signaling to Rac1 in blood 
vessel formation and vascular permeability.  In addition, this research will characterize a 
few of the key proteins involved in either coupling VEGF signaling to Rac1 activation 
during endothelial cell migration or acting downstream of Rac1 to compromise 
endothelial barrier function.  However, this chapter will begin by providing an historical 
perspective of VEGF signaling and Rho GTPases, with an emphasis on their respective 
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roles in endothelial cell biology.  Later, this chapter will focus on the specific proteins 
that facilitate endothelial cell migration or vascular permeability based on our recent 
scientific findings. 
 
VEGF signaling pathway 
  
 VEGF signaling is critical for vascular development since its presence often 
serves as a rate-limiting factor in normal and disease states.   In normal physiology, 
VEGF is necessary for the differentiation of hemangioblasts to angioblasts and the 
formation of a vascular plexus in vasculogenesis; also, gradients of VEGF facilitate the 
proliferation and sprouting of endothelial cells from pre-existing vessels14,31,32.  As a 
permeability factor, VEGF can also cause fenestrations in endothelial cells that decreases 
intracellular contacts33.  Although VEGF is not required for all vascular permeability 
events, it plays a strong role in the pathogenesis of numerous inflammatory diseases7,10.   
Thus, elucidating the molecular mechanisms that act downstream of VEGF signaling can 
lend insight into how to develop pharmaceutical targets that will prevent or ameliorate 
vascular-related diseases. 
VEGF ligands 
The VEGF ligand family is comprised of seven secreted, dimeric glycoproteins 
with molecular weights ranging from 21-40kDa.  These ligands are products of multiple 
alternative splicing and proteolytic processing events. Five of the seven VEGF ligands 
exist in mammals: VEGF-A, VEGF-B, VEGF-C, VEGF-D, and placental growth factor 
(PlGF).  Studies have shown that VEGF-A and VEGF-C are essential for the creation of 
blood and lymphatic vasculature during embryogenesis, whereas VEGF-B, VEGF-D, and 
PlGF are not required for blood vessel formation5,34-36. The two other VEGF ligands, 
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VEGF-E and VEGF-F, are structurally similar, but are expressed in viral homolog 
parapoxvirus and snake venom, respectively37,38.  For the purposes of this discussion, we 
will focus on the most effective positive mediator of VEGF signaling, VEGF-A.   
VEGF-A, the first identified member of the VEGF ligand family, is expressed in 
nearly all vascularized adult tissues suggesting its importance in maintaining vascular 
homeostasis39.  Initially, VEGF-A was termed vascular permeability factor (VPF) 
because of its ability to induce endothelial junction disassembly, but subsequently it has 
been studied for its survival, proliferation and vascularization effects as well19. Other 
secreted growth factors and cytokines such as platelet-derived growth factor (PDGF), 
epidermal growth factor (EGF), tumor necrosis factor-α (TNF-α) and interleukin-1 (IL-1) 
can stimulate VEGF-A gene expression in endothelial cells40.  In addition, changes in the 
vascular microenvironment such as low pH and hypoxia can induce VEGF-A gene 
expression by upregulating hypoxia-inducible factor-1α (HIF-1α)41.  After expression 
and proteolytic processing, soluble VEGF-A can bind many receptors on pluripotent 
hematopoietic stem cells, leukocytes, neurons, smooth muscle cells, and osteoblasts in 
addition to endothelial cells40,42.  As a potent survival factor, VEGF-A can initiate anti-
apoptosis signaling cascades in endothelial cells43,44.  VEGF-A also upregulates nitric 
oxide (NO) production in endothelial cells through endothelial nitric oxide synthase 
(eNOS) to cause vessel dilation; equally, NO can mediate VEGF activation of the 
mitogen-activated protein kinase (MAPK) signaling pathways45,46.  The importance of 
VEGF-A for blood vessel formation was demonstrated by seminal work that showed 
inactivation of a single Vegfa allele is embryonic lethal in mice due to incomplete 
endothelial cell development and immature vascular networks4,5. 
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Like other VEGF ligands, VEGF-A is composed of two monomers connected by 
disulfide bonds consisting of eight conserved cysteine residues organized in an anti-
parallel fashion, thus making the molecule dimeric. Although, the majority of VEGF 
ligands prefer to form homodimers, VEGF-A and PlGF also form heterodimers according 
to crystal structure analysis47 . Human VEGF mRNA is alternatively spliced to encode 
five isoforms (VEGF121, VEGF145, VEGF165, VEGF189, and VEGF206) though less 
commonly expressed isoforms (VEGF165b and VEGF183) have also been identified42,48.  
Of note, the subscript number represents amino acid length. 
Of these isoforms, VEGF165, VEGF121, and VEGF189, are the most widely studied 
with VEGF165 being classified as the predominant signaling isoform in both normal and 
disease situations. Early work by Houck et al. (1992) characterized these three 
polypeptides by their amino acid length and composition. They found that the shortest 
isoform, VEGF121, was released freely by human embryonic kidney (HEK) cells in 
proteolysis studies because it lacked a critical domain for binding heparin, a highly 
sulfated glycosaminoglycan found in extracellular matrix (ECM). VEGF189, which does 
contain the heparin-binding domain, was secreted but was almost entirely bound to the 
ECM or cell surface.  VEGF165 demonstrated an intermediary behavior; however, later 
studies showed that VEGF165 requires heparin for receptor interactions49,50.  This ability 
to bind substrate while retaining soluble properties provides a dual availability that may 
contribute the importance of VEGF165 in the major vascular activities.   VEGF121 and 
VEGF189 have also been studied for their respective roles in blood vessel formation and 
permeability, but the rest of this discussion will emphasis the significance of VEGF165 in 
endothelial cell function51-54.    
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Expression of VEGF165 is upregulated in many physiological situations including 
exercise-induced angiogenesis and tissue repair after injury as well as pregnancy and 
during the menstrual cycle in females40,41.  As it pertains to disease, this isoform is 
overexpressed in many solid tumors and is a strong biomarker of disease reoccurrence in 
cancer patients55,56. Increased VEGF165 expression is also found in atherosclerotic 
plaques with abundant macrophage invasion suggesting that dysregulated concentrations 
of this molecule can cause aberrant vascular permeability and pro-inflammatory effects57.  
In pregnant females, upregulated VEGF165 in the newly-vascularized uterine cavity is 
associated with risk for preclampsia58.  Ironically, splice variant VEGF165b has been 
shown to negatively regulate VEGF receptor downstream signaling48.  Despite the 
expression of the other VEGF isoforms in many vascularized tissues, VEGF165 has been 
characterized as the most powerful stimulator of proliferation and blood vessel formation 
and is essential for physiological and pathological vascular events59-62.   
VEGF signaling is dictated by its ability to bind different VEGF receptors and co-
receptors, such as neuropilins.  VEGF exerts its biological effects through structurally 
related transmembrane receptor tyrosine kinases known as VEGF receptors.   In addition, 
VEGF binds co-receptors that possess VEGF affinity but lack catalytic functions.  VEGF 
overlaps in its affinity for binding to these receptors and co-receptors depending on the 
necessary biological activity.  These VEGF ligand and receptor combinations are 
illustrated in Figure 1.1.  In the next section, we will discuss how VEGF interacts with 
and signals via its receptors and co-receptors to apply its effects on endothelial cells. 
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VEGF receptors  
There are three VEGF receptors: VEGF receptor-1 (VEGFR-1), also known as 
Flt-1; VEGF receptor-2 (VEGFR-2), also known as KDR or Flk-1; and VEGF receptor-3 
(VEGFR-3), also known as Flt-4.  These receptors have multiple extracellular 
immunoglobin (Ig) homology domains, a single transmembrane region, and intracellular 
tyrosine kinase domains.  Like VEGF ligands, VEGF receptor expression may be 
upregulated by environmental stimuli such as hypoxia via a HIF-1-dependent 
mechanism42,63.  VEGFR-1 and VEGFR-2 are expressed on vascular endothelial, 
neuronal, and immune cells, whereas VEGFR-3 is expressed on lymphatic endothelial 
cells.   Despite similar tissue expression, VEGFR-1 and VEGFR-2 loosely overlap in 
their ability to bind VEGF ligands.  VEGFR-1 can bind VEGF-A, VEGF-B and PlGF, 
yet VEGFR-2 binds VEGF-A, VEGF-C, VEGF-D, and VEGF-E.  The unique role of 
VEGFR-3 in lymphatic vessel formation is evident in its ability to bind VEGF-C and 
VEGF-D, which both play major roles in stimulating lymphangiogenesis and lymphatic 
metastasis64-67. VEGF ligands bind to the extracellular domain of VEGF receptors, thus 
causing the receptor to dimerize and autophosphorylate its intracellular kinase domains. 
These events ultimately activate the receptor.  Receptor activation then propagates a 
signaling cascade that promotes survival, proliferation, and migration of vascular and 
lymphatic endothelial cells.  In fact, these receptors can also form homodimers or 
heterodimers to transduce downstream signals. Studies have shown that VEGFR-1 
negatively affects VEGF actions by either sequestering soluble VEGF or physically 
inhibiting VEGFR-2 signaling, whereas VEGFR-2 is characterized as the major regulator 
of endothelial cell proliferation, migration, and permeability14.  Therefore, we will focus 
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on the positive signaling effects of VEGFR-2 on endothelial cell behavior. 
 First isolated in 1991 under the name Kinase-insert Domain containing Receptor 
(KDR), VEGFR-2 is produced as a precursor polypeptide that undergoes two 
glycosylation steps to become a mature protein expressed on the cell surface68,69.  
Seminal work by Millauer et al. (1993) showed that VEGFR-2 (known as fetal-like 
kinase (Flk-1) in mice) is essential for vasculogenesis and angiogenesis in murine 
embryonic development70.  Genetic deletion of Vegfr2 causes embryonic lethality due to 
severe defects in blood island formation, leaky vasculature, and decreased numbers of 
endothelial cells3.  Expression of VEGFR-2 is upregulated in angiogenic blood vessels, 
but decreased in quiescent vascular endothelial cells71.  Also, VEGFR-2 expression can 
inhibit apoptosis of capillary-derived endothelial cells in vivo and human umbilical veins 
endothelial cell (HUVECs) in vitro72,73.  A role for VEGFR-2 in vascular permeability is 
evident in work by Langille et al. (2001) that reported shear stress caused VEGFR-2-
induced endothelial barrier dysfunction in the absence of VEGF74. Importantly, these 
collective studies illustrate that VEGFR-2 signaling is required for normal endothelial 
cell survival and behavior.   
Similar to other VEGF receptors, the binding of VEGF toVEGFR-2 initiates 
dimerization and tyrosine (Tyr) phosphorylation of several key C-terminal residues. 
Phosphorylation of these C-terminal residues provides docking sites for a number of SH2 
domain-containing signaling molecules such as phospholipase-Cγ (PLCγ) and 
phosphatidylinositol-3-OH kinase (PI3K) as well as adaptor molecules like Shb68,75,76. 
Two of these critical residues, Tyr1175 and Tyr1214, are phosphorylated upon VEGF-A 
binding; further, Tyr1175 phosphorylation is important for endothelial cell 
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proliferation63,71. Interestingly, mice overexpressing a phosphorylation defective Tyr1173 
(a mouse Tyr1175 homolog) mutant die by embryonic day 9.5 (E9.5) because of an 
underdeveloped vasculature similar to Vegfr2 knockout mice77.   The 
autophosphorylation of  two other tyrosine residues, Tyr1054 and Tyr1059, in the 
activation loop of its kinase domain is required for optimal kinase activity78.   In recent 
years, pharmacological inhibitors such as monoclonal antibodies have been developed to 
target and block VEGFR-2 signaling63.    
VEGF signaling through VEGFR-2 stimulates a myriad of signaling molecules to 
confer its biological effects.  As a means of inducing vascular permeability, VEGFR-2 
has been shown to signal through PLCγ, eNOS,  and PKC79.  VEGFR-2 signaling can 
facilitate endothelial cell survival via the PI3K/Akt pathway, which inhibits stress-
activated p38 MAPK80,81.  Conflicting evidence by Ferrari et al. (2006) showed that 
VEGFR-2, which is normally pro-survival, can induce endothelial cell apoptosis through 
transforming growth factor-β (TGF-β) and p38 MAPK82.  Signaling through p38 MAPK 
can also act upstream of migratory events83.  VEGFR-2 signaling to p38 MAPK may 
serve as a regulatory switch in endothelial cell activities because it has been implicated in 
many signaling pathways.  Non-receptor tyrosine kinase Src and focal adhesion kinase 
(FAK) also propagate VEGFR-2 signaling by phosphorylating cell-cell and cell-ECM 
adhesion molecules to regulate barrier function, respectively28,84.  With respect to small 
GTPases, VEGF stimulates activation of Ras in HUVECs, which leads to angiogenesis in 
these cells85.  VEGFR-2 can stimulate endothelial cell proliferation through the MAPK 
pathway in a Ras- and PLCγ-dependent manner68.  Close relatives to Ras proteins, 
members of the Rho family of small GTPases are also activated downstream of VEGFR-
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2 to mediate migration, adhesion, and proliferation by reorganizing the actin 
cytoskeleton26,86.  We will address the influence of VEGFR-2 signaling on Rho GTPases 
in the next section of this chapter. 
VEGFR-2 plays a prominent role in the progression of vascular-associated 
diseases, particularly cancer.  Vosseler et al. (2005) showed that blockade of VEGFR-2 
signaling inhibits angiogenesis and the dissolution of ECM by matrix metalloproteases 
(MMPs) in epithelial tissue-derived tumors87.  In athymic nude mice, brain glioblastoma 
growth is downregulated by retroviral infection of a dominant negative VEGFR-288.  
Besides traditional neoplastic-related angiogenesis, VEGFR-2 has been implicated in 
other diseases that require VEGF signaling such as human immunodeficiency virus-1 
(HIV)-associated Kaposi sarcoma, a vascular disorder characterized by inflammation and 
reddish-color bruises on the skin and mouth. In this fascinating pathology, HIV-1 Tat 
protein activates VEGFR-2 and retrieves basic fibroblastic growth factor (bFGF) from 
ECM to provide a substrate for nascent blood vessel formation and pericyte binding54,89.  
Additionally, increased permeability during inflammation is mediated by VEGFR-2, 
which is activated by VEGF secreted from leukocytes, particularly in atherosclerosis, 
asthma, and psoriasis6,90-92.  Dysregulated VEGFR-2 signaling has also been implied in 
diseases in which vessel growth is not the primary pathogenesis, but the vessels remodel 
abnormally by pruning or vessel enlargement, for example in hypertension6.   
Interestingly, inhibition of VEGFR-2 can increase tumor cell death in response to 
radiation, thus providing additive treatment and protection against tumor growth93. Gene 
therapy targeting VEGFR-2 is also used to treat ischemia of the heart myocardium7.  
Recent efforts by many laboratories have developed antibodies and small molecules to 
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bind and block VEGFR-2 kinase activity; thus, providing therapeutic approaches to alter 
endothelial cell behavior in aberrant angiogenic and permeability conditions. 
To exert these effects in normal health and disease, VEGFR-2 utilizes the aid of 
several accessory proteins known as co-receptors to synergize and tightly regulate its 
signaling in different biological functions.  Next, we will discuss how these co-receptors 
are imperative to differentiate VEGF signaling in endothelial cell migration and 
permeability. 
VEGF co-receptors  
  
VEGF signaling has profound effects on endothelial cells, but these signaling 
mechanisms must be regulated on many levels to ensure the correct biological outcome.  
Therefore, co-receptors such as neuropilins, αv integrins, heparan sulfate proteoglycans, 
and Vascular Endothelial (VE)-cadherin, promote endothelial cell behavior by directing 
VEGF signals to the appropriate location, controlling signal intensity or duration as well 
as coordinating the activation of downstream molecules.  Neuropilins, namely neuropilin-
1 and -2 (NP-1 and NP-2), were initially characterized as non-tyrosine kinase receptors 
that mediate axon guidance and neuronal development through class-3 semaphorins. 
However, work from several groups has demonstrated a positive role for neuropilins in 
normal and disease-associated blood vessel formation 94-98.  NP-1 and NP-2 can bind 
VEGF ligands and receptors in vitro.  Association of NP-1 and NP-2 with VEGFR-2 can 
modulate survival, proliferation, and migration of endothelial cells; however, the 
biological function of their interaction with VEGFR-1 is unknown99,100.  Integrins have 
been shown to coordinate growth factor signaling for many years.  Integrins are a large 
family of integral membrane homodimers composed of α and β subunits.  These proteins 
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mediate cell-ECM adhesion by binding to the cellular domain of matrix proteins such as 
fibronectin, vitronectin, and collagen.  Work by many groups have showed that integrins 
and VEGF receptors are linked functionally and physically to influence communication 
between endothelial cells and their substrate ECM.  Integrins of the αv subfamily are 
highly expressed in endothelial cells and have a strong affinity for binding fibronectin 
and vitronectin substrates.  VEGFR-2 interaction with αvβ5 (a receptor for vitronectin) at 
the cell-ECM interface may promote vascular permeability and angiogenesis by binding 
to its extracellular domain101,102.  In vivo studies showed that VEGF signaling is 
dependent on integrin αvβ5 activation, and integrin αvβ3 activation to a lesser extent 
because β3 integrin may be playing a negative regulatory role in VEGF signaling103,104 .  
Another molecule that plays a supporting role in VEGF signaling is heparan sulfate 
proteoglycan, or HSPG.  Proteoglycans are macromolecules consisting of a core protein 
with covalently attached one or multiple polysaccharide chains of the glycosaminoglycan 
such as heparan sulfate or heparin.  When these proteoglycans are synthesized and 
secreted by the cell, they aggregate and interact with other basement membrane 
molecules to form the ECM.  HSPG is an abundant component of all basement 
membranes105.  Early work demonstrated that HSPG plays a major role in endothelial cell 
adhesion and migration through integrins.  HSPG have a high affinity for VEGF ligand; 
specifically it is a target for VEGF-A165 or VEGF-A189 that contains a domain for binding 
heparan sulfate and heparin binding. In addition, HSPG amplifies signaling by VEGF-
A165 through VEGFR-2106.  It is theorized that HSPG forms complexes with growth 
factor receptors to increase the half-life of  signal duration and magnitude; but to date, 
this has not been shown specifically for VEGF receptors107.  Neuropilins, αv integrins, 
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and HSPGs have important, but complex partnerships with the VEGF signaling pathway 
to modulate vascular development and maintenance.  Next, we will concentrate on the 
role of VE-cadherin because of its significant influence on VEGF-induced vascular 
permeability. 
VEGF receptors have a vital role in cell-cell adhesion and communication 
through their direct association with adhesion molecules.  The localization of VEGFR-2 
on endothelial cells may facilitate in determining specific biological processes after 
VEGF stimulation.  VEGFR-2 can interact with adhesion molecule VE-cadherin at cell-
cell junctions, which may aid in both vascular permeability and blood vessel formation.  
Cadherins are adhesion proteins that are mainly homophilic, but sometimes heterophilic, 
and bind in a calcium-dependent manner.  Moreover, cadherins are the major 
transmembrane proteins of cell-cell adhesions called adherens junctions.  These adhesive 
interactions are created when the cadherin extracellular domains is linked to the internal 
actin cytoskeleton through a series of proteins that associate with the cadherin 
cytoplasmic domain108,109.  VE-cadherin (also known as cadherin-5/CD144) is one of 
three types of cadherin expressed in endothelial cells110.  A second isoform of VE-
cadherin (VE-cadherin 2) was identified, but it was unable to bind linking proteins and 
did not appear to have a role in permeability111. Inhibition of VE-cadherin binding with 
function blocking antibodies decreases endothelial cell barrier integrity, while increasing 
leukocyte TEM in vivo112.  Kevil and colleagues showed that VEGF stimulation 
disorganizes VE-cadherin localization in vascular permeability.  It was later discovered 
that this disorganized localization was due to loss of contact with the actin cytoskeleton 
from endocytosis of VE-cadherin from the cell surface and involves the adaptor molecule 
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β-arrestin2113-115.  Conversely, VE-cadherin can also regulate endocytosis of VEGFR-2 
and its signaling from early endosome antigen-1 (EEA-1)-positive vesicles in 
HUVECs116.  In knockout studies, genetic deletion of VE-cadherin in mice causes 
embryonic lethality at E9.5 as a result of impaired blood vessel remodeling and 
maturation117.  In disease, upregulated expression of VE-cadherin has also been detected 
in hemangiomas (blood vessel-derived tumors) and the retinas of diabetic patients118,119.   
As a co-receptor for VEGFR-2, VE-cadherin localizes and intensifies VEGF 
signals to proteins at endothelial junctions that are involved in vascular permeability. 
VEGFR-2 and VE-cadherin forms a complex that transiently and quickly dissociates after 
VEGF treatment in mouse cardiac cells, suggesting that complex formation is a 
mechanism for localized cell-cell disruption by VEGF28.  Tyrosine phosphorylation of 
VE-cadherin in response to VEGF has been observed in quiescent and angiogenic tissues 
as well as cultured endothelial cells in a Src- or Yes-dependent manner28,120. Work from 
the same group demonstrated in vitro that VE-cadherin is tyrosine phosphorylated on 
residue 685 after VEGF stimulation downstream of Src kinase activity, but it remains 
elusive whether this phosphorylation is VEGFR-2-dependent121. Moreover, in vivo, Src 
and Yes kinase activity is required for phosphorylation of adherens junction proteins, 
resulting in leakage of blood vessels.  Conversely, mice devoid of either kinase display 
defects in endothelial cell permeability after VEGF treatment28. Src phosphorylates two 
other key tyrosine residues of VE-cadherin, Tyr658 and Tyr731.  Tyrosine 
phosphorylation of these residues block binding of two adherens junction proteins to 
cause permeability, p120catenin and β-catenin, respectively122.  Interestingly, work by 
Gavard et al. (2006) illustrated that another residue, namely serine 665 (Ser665), is 
 17
phosphorylated downstream of VEGFR-2 and regulates VEGF-dependent VE-cadherin 
endocytosis, which promotes endothelial cell permeability115. Phosphorylation of these 
proteins disrupts cell-cell junctions, thus decreasing endothelial cell barrier function. 
However, it is unknown if VEGF signaling or VEGFR-2 interaction is mediating these 
phosphorylation events. Despite its positive effects on permeability, VE-cadherin 
negatively regulates endothelial cell growth by binding VEGFR-2 and preventing its 
downstream signaling117,123,124. As it pertains to other biological processes, VEGF-
A/VEGFR-2/VE-cadherin complex formation also has a role in endothelial cell survival.  
When the cytoplasmic domain of VE-cadherin is removed in vivo, complex formation 
with VEGFR-2 binding is blocked, subsequently inhibiting PI3K and Akt activation 
required for anti-apoptosis signaling117.  Clearly, VE-cadherin coupling to VEGFR-2 may 
create gaps in endothelial cell monolayer, allowing leukocytes transmigrate across the 
endothelium during immune response. In addition, this complex may be important for 
other processes required for cell homeostasis. In addition to this discussion, these co-
receptors are illustrated in Figure 1.1.  Together, these co-receptors affect the duration, 
localization, and quality of VEGF receptor signaling.  However, activated downstream 
molecules must tightly regulate these signals to prevent inappropriate temporal or spatial 
permeability and blood vessel formation.  The next section will address how these signals 
affect a family of proteins that strongly influence endothelial cell behavior through actin 
reorganization, the Rho family of small GTPases.  
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Figure 1.1  Model of VEGF ligands, receptors, and co-receptors.   
 
(A)  VEGF ligands and receptors. This schematic represents the seven vascular growth 
factor ligands (placental growth factor (PlGF), VEGF-A, -B, -C, -D, -E, and -F) and their 
cognate receptors (VEGFR-1, -2-, and -3).  Isoforms of the VEGF-A ligand subfamily 
(VEGF165, VEGF121, and VEGF189) are essential for blood vessel formation and vascular 
permeability. The asterisk (*) indicates that VEGF-F, which has 50% homology to 
VEGF-A, is an unconventional ligand isolated from snake venom.  On the right, the 
intracellular domains of the VEGF receptors are also shown including the transmembrane 
domain (TM), the juxtamembrane domain (JM), the first tyrosine kinase domain (TK1), 
the kinase insert (KI), the second tyrosine kinase domain (TK2), and the C-terminal tail 
(CT).  Phosphorylation of critical tyrosine residues in the CT are important for receptor 
activation, protein scaffolding, and downstream signaling to effectors.  (B) VEGF Co-
receptors.  Neuropilins, heparan sulfate proteoglycans, VE-cadherin, and αv integrins 
have been shown to facilitate in VEGF receptor signaling. These accessory receptors 
modulate binding of certain, but not all VEGF ligands, to the main receptors as a means 
of intensifying signaling events. (Model adapted from Claesson-Welch, Biochem Soc 
Trans, 2003 and Olsson et al., Nature Rev, 2006) 
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VEGF signaling to Rho family of Small GTPases 
  
 Intracellular signaling downstream of VEGF controls many endothelial cell-
specific functions such as migration preceding blood vessel formation and permeability 
that allows leukocyte TEM during immune surveillance and response.  The Rho family of 
GTP-binding proteins, or simply Rho GTPases, has been implicated in several aspects of 
vascular biology by influencing the behavior of endothelial cells and other cell types. Rho 
GTPases do this by mediating the cytoskeletal changes required for these functions.  Rho 
GTPases, part of the larger Ras superfamily, are low molecular weight (~20kDa) 
molecules and have approximately 25% homology with Ras.  First identified in 1985, 
many related Rho GTPases have been characterized in mammals with 20 proteins 
discovered to date. The most-studied GTPases are proteins of the Rho (RhoA, RhoB, 
RhoC), Cdc42 (Cdc42, TC10, TCL, Wrch-1/-2) and Rac (Rac1, Rac2, Rac3, RhoG) 
subfamilies.  Other Rho GTPase subfamilies include RhoD, RhoH, Rnd, Rif, RhoBTB, 
and Miro22,125.  Collectively, these proteins regulate general cell maintenance processes 
including gene expression, proliferation, and apoptosis as well as specific activities such 
as cell motility, adhesion, and vesicle trafficking22,126. Many of the cellular effects and 
biological functions of these Rho GTPases are listed in Table 1.1. 
Rho proteins act as molecular switches that cycle from an inactive GDP to active 
GTP-bound states to become activated.  These GTPases have distinct pockets for 
nucleotide- and Mg2+-binding. Mg2+ is required for high-affinity nucleotide binding. In 
the GTP-bound state, these proteins interact with target proteins to induce cellular 
responses.  Since the intrinsic rate of nucleotide exchange on Rho proteins is low, GDP-
GTP cycling is accelerated by guanine nucleotide exchange factors (GEFs). Many GEFs 
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only activate specific Rho GTPases, whereas some GEFs are more promiscuous so they 
activate multiple GTPases depending on the upstream stimuli.  Activation of Rho 
GTPases by GEFs has been shown to stimulate translocation of these proteins (e.g., Rac 
and Cdc42) from the cytoplasm to the plasma membrane where they can interact with 
downstream effectors20.  Conversely, GTPase-activating proteins (GAPs) hydrolyze the 
gamma phosphate (Pι) on GTP to convert Rho proteins back to an inactive GDP-bound 
state.  Inactive Rho GTPases then bind guanine nucleotide-dissociation inhibitors (GDIs) 
to prevent membrane and adhesion targeting.  Many GTPases are post-transcriptionally 
modified by prenylation at their C-termini at a conserved cysteine to facilitate membrane 
targeting, and GDIs bind to this site to inhibit their interaction with plasma membranes.  
This GDP-GTP cycling is illustrated in Figure 1.2.  Protein expression, phosphorylation, 
and membrane targeting are a few of the mechanisms that regulate the function of these 
proteins.  
Rho GTPases and their regulatory proteins have been shown to mediate vascular 
development and function during response to numerous stimuli including VEGF.  During 
directed migration towards VEGF, Rho proteins regulate cell shape and adhesion to 
ensure that the cell has a single protrusive front and retracting back end20.  In addition, 
these proteins induce cell contractility and fenestrations that create openings between 
endothelial cells to make a passage for entry into or exit from the bloodstream.  The next 
section will further discuss how RhoA, Cdc42, and Rac1 facilitate migration and 
permeability with an emphasis on Rac1 because it is a strong driving force in altering the 
actin cytoskeleton these processes. Many of these examples are illustrated in Figure 1.3. 
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TABLE 1.1 Rho GTPases, Regulators, and Functions 
Family 
Member 
Cellular                   
Effects 
Biological 
Function 
Refs 
Rho 
RhoA* 
RhoB 
RhoC 
 
Rac 
Rac1* 
Rac2 
Rac3 
RhoG 
 
Cdc42 
Cdc42* 
TC10 
TCL 
Chp/Wrch-1 
Wrch-2 
 
Rnd 
Rnd1 
Rnd2 
Rnd3/RhoE 
 
 
RhoBTB 
RhoBTB-1 
RhoBTB-2 
RhoBTB-3 
 
Miro 
Miro-1 
Miro-2 
 
RhoD and Rif 
 
 
 
RhoH 
 
Stress Fiber Formation 
Contractility 
 
 
 
Lamellipodia Formation 
Membrane Ruffles 
 
 
 
 
Filopodia Formation 
 
 
 
 
 
 
Stress Fiber Disassembly 
Loss of Contractility 
 
 
 
 
Unknown 
 
 
 
 
Unknown 
 
 
 
Stress Fiber Disassembly (RhoD) 
Filopodia Formation (Rif) 
 
 
 
Unknown (Hematopoietic cells) 
Cell Adhesion 
Cell Proliferation 
Gene Expression 
Vesicle Trafficking 
 
Cell Polarity 
Cell Migration 
Neurite Extension 
Gene Expression 
 
 
Environment    
Sensing 
Cell Polarity 
Cell Migration 
Neurite Extension 
Neuron Survival 
 
Cell De-adhesion 
Cell Rounding 
Cell Survival 
 
 
 
Cell Proliferation 
 
 
 
 
Apoptosis 
Mitochondrial 
Trafficking 
 
Cell De-adhesion 
Cell Immobility 
Vesicle Trafficking 
 
 
Apoptosis 
Cell Proliferation 
 
 
21,126 
 
 
 
20,23,127 
 
 
 
 
 
128,129 
 
 
 
 
130-132 
 
 
 
133 
 
 
 
 
134,135 
 
 
136-139 
 
 
 
140,141 
 
 
 
 
 
* Extensively discussed in dissertation 
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Table 1.1  Rho Family of Small GTPases and Functions 
 
This table highlights the members of Rho GTPase family, their effects on cellular 
morphology, and a few of their known biological functions. 
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Figure 1.2  Model of GTPase cycling and regulation.   
This model illustrates the prototypical GDP-GTP exchange of Rho GTPases and its 
regulatory proteins.  This process includes the activation of GTPases by GEFs via 
exchange of GDP for GTP, signaling to downstream effectors, inactivation of GTPases 
by GAPs by dissociating the gamma phosphate (Pi) on GTP to convert back to GDP, and 
sequestration of GDP-bound protein to cytoplasm by GDI. 
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Figure 1.3  Model of VEGF signaling to Rho family of small GTPases. 
This model illustrates how VEGF signaling through the Rho family of small GTPases 
(Rho, Rac, and Cdc42) confers different effects on endothelial cell morphology, 
functions, and behavior. 
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Cell migration 
The process of cell migration is divided into four individual steps:  lamellipodia 
extension, the formation of nascent adhesions, cell body contraction, and rear tail 
retraction. RhoA, Cdc42, and Rac1 have been closely studied for their respective roles in 
each one of these steps and these are illustrated in Figure 1.4.  Rho promotes formation of 
stress fibers and focal adhesions.  The tension formed by stress fibers and actomyosin 
bundles cause cell body contraction that propels endothelial cells forward during 
migration, whereas focal complexes form the new adhesions that stabilize the cell on 
ECM.  These focal complexes later mature into focal adhesions that “permanently” bind 
substrate. RhoA also regulates rear tail retraction of migrating cells, but its level of 
activity in tail detachment varies based on the cell type. Fibroblasts have large focal 
adhesions and therefore decreasing RhoA may promote migration by disassembling the 
focal adhesions in the tail of the cell142. VEGF signaling to RhoA has been shown to 
mediate stress fiber formation and actomyosin contractility during endothelial cell 
migration and assembly into pre-capillary cords26,143-145.  So far, there is no indication 
that VEGF signaling can mediate RhoA-dependent tail retraction.  
Cdc42 induces finger-like membrane protrusions called filopodia that allows cells 
to sense their immediate microenvironment and may be a precursor structure for leading 
edge protrusion of motile cells.  The ability of Cdc42 to promote actin polymerization is 
modulated by Wiskott Aldrich Syndrome Protein (WASP) proteins, which nucleate the 
formation of linear actin bundles by the Arp2/3 complex.  VEGF-induced Cdc42 
activation can lead to endothelial cell proliferation  and actin reorganization into 
filopodial extensions during chemotaxis as well as blood vessel sprouting during 
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angiogenesis146-148.  The exact mechanism by which VEGF stimulates Cdc42 activity 
remains poorly characterized.   
Rac1 stimulates sheet-like lamellipodia and membrane ruffles at the leading edge 
and dorsal surface of migrating cells.  Lamellipodia and membrane ruffles are structurally 
similar, and commonly lamellipodia regress into ruffles when nascent adhesions are 
unstable on ECM.  In actuality, membrane ruffles are thought to promote the engulfment 
of large molecules (macropinocytosis) rather than cell migration, unlike lamellipodia. 
Seminal work by Ridley and colleagues reported that a constitutively active mutant of 
Rac1 (V12Rac1) induces membrane ruffles in response to growth factors and 
overexpression of a dominant negative Rac1 mutant (N17Rac1) suppressed these 
ruffles149.  Also, Rac1 is required for lamellipodia formation and subsequent migration in 
response to growth factors because dominant negative Rac1 inhibited this 
phenotype20,23,150.  Activation of Rac1 downstream VEGF signaling promotes 
lamellipodia formation through WASP-family veroprilin homologous protein (WAVE) 
proteins127.  WAVE proteins behave similar to WASP proteins by activating the Arp2/3 
complex to nucleate actin filaments, but they create a branched network of actin filaments 
instead of linear bundles and do not directly bind Rac1.  Work by Yamazaki et al. (2003) 
illustrated that Rac1 is required for VEGF-induced lamellipodia formation in motile 
endothelial cells151.  Rac1 is also activated during integrin-mediated adhesion to matrix 
protein laminin in endothelial cells, suggesting it plays a dual role in migration147.   
In comparison to other Rho GTPases, Rac1 may arguably play the most important 
role in migration with the formation of lamellipodia at the leading edge of cells. 
Lamellipodia not only polarize the cell in the direction of chemotactic stimuli, but they 
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may also concentrate VEGFR-2 at the leading edge to synergize and intensify the VEGF 
signal.  Many groups have characterized the mechanisms underlying Rac1-mediated 
lamellipodia formation.  Extracellular stimuli can activate numerous cell surface 
receptors such as VEGFR-2, which subsequently activate PI3K.  Activation of PI3K 
generates phosphatidylinositol (4,5)-bisphosphate (PIP2) and phosphatidylinositol (3,4,5)-
trisphosphate (PIP3) in the plasma membrane.  VEGF has been shown to activate PI3K in 
endothelial cells152.  Although inhibition of PI3K prevents Rac1 activation in numerous 
cell types, it is unknown if this occurs in endothelial cells152-155.  PIP2 and PIP3 may serve 
as lipid substrates where Rac1 is activated; in addition, they uncap barbed ends of actin 
filaments at the leading edge156,157. These lipid substrates also localize other molecules 
required for Rac1 activation such as tyrosine kinase Src and GEFs such as Vav proteins 
to the plasma membrane158.  Once Rac1 is activated by the appropriate GEF(s), it can 
stimulate actin polymerization to form lamellipodia through a number of proteins such as 
WASP-family veroprilin homologous protein (WAVE). WAVE proteins stimulate the 
formation of a branched actin network by binding to the p21 subunit of the Arp2/3 
nucleating complex, which is located on the sides of pre-existing filaments. Rac mediates 
WAVE-dependent actin nucleation through insulin receptor substrate p53 (IRSp53), a 
substrate for the insulin receptor with unknown function.  Miki and colleagues discovered 
that IRSp53 was the missing link between Rac1 and WAVE since it was shown 
previously that Rac1 did not bind WAVE directly. IRSp53 can also interact with Cdc42, 
but at a different binding site159.  When IRSp53 binds to WAVE, it then promotes WAVE 
association with the p21 subunit of the Arp2/3 nucleating complex, which polymerizes 
actin by uncapping actin filaments similar to the actions of PIP2157. The branched network 
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structure is controlled by Arp2/3, which binds at exactly 70° to the sides and pointed ends 
of actin filaments and extends forward in the route of protrusion160. In addition to actively 
stimulating actin polymerization, Rac1 can inhibit actin depolymerization as a means of 
indirectly promoting lamellipodia formation. Rac1 does this by binding and activating 
PAK to slow the rate of actin depolymerization.  PAK, which can also bind Cdc42, then 
stimulates LIM kinase (LIMK).  LIMK in turn phosphorylates and inactivates cofilin, a 
protein that severs actin filaments and promotes their depolymerization161.  Thus, Rac1 
inhibits actin depolymerization by blocking cofilin function.  In contrast, there are studies 
that suggest cofilin upregulates lamellipodia formation and cell migration by generating 
more actin monomers for barbed end polymerization162,163.  VEGF can lead to rapid 
phosphorylation of cofilin in a LIMK-dependent manner, but PAK was not involved in 
LIMK activation164.  Although the role of VEGF at each level of this signaling cascade 
has not been fully characterized, data established in other cell types suggest these 
mechanisms may be similar in endothelial cells. A schematic of the proteins involved in 
Rac1- and Cdc42-mediated actin polymerization during VEGF-induced chemotaxis is 
illustrated in Figure 1.5.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 32
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cdc42 and Rac extends the leading 
edge of cell to establish polarity 
(filopodia and lamellipodia)
1
2
Rac and Rho form new 
adhesion on ECM                   
(focal complexes)
3
Rho contracts the 
cell body to propel it 
forward4
Rho retracts the tail end 
to maintain polarity
Directional movement of polarized cell
During this process, 
migrating cells 
releases proteases 
that cleave ECM 
proteins
 33
Figure 1.4 Model of proteins involved in endothelial cell migration.  
In this model, a migrating cell polarizes and moves in the direction of a stimulus. This 
process is as follows: 1) the migrating cell first establishes polarity by extending 
membrane protrusions, namely filopodia and/or lamellipodia, at the leading edge in a 
Cdc42- and Rac-dependent manner; 2) these protrusions are stabilized by nascent, 
transient adhesions to the underlying extracellular matrix (ECM) called focal complexes.  
During this time, the cells also secrete proteases that cleave surrounding matrix proteins 
to crave out a pathway for movement; 3)  the cell body is propelled forward by Rho-
mediated contraction; 4) the tail dissolves adhesions to the ECM while Rho facilitates tail 
retraction. This step aids in maintaining polarity and forward movement. (Model adapted 
from Ridley, JCS, 2001) 
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Figure 1.5  Model of lamellipodia formation during VEGF chemotaxis. 
This model illustrates the proteins involved in lamellipodia formation during the 
chemotaxis of an endothelial cell towards VEGF.  This process is as follows:  1) VEGFR-
2 on the cell surface recognizes the chemoattractant gradient of VEGF; 2) 
Phosphatidylinositol (4,5)-bisphosphate (PIP2)  is produced on the plasma membrane to 
serve as a substrate for Rac1 and Cdc42 translocation. Concurrently, Src family tyrosine 
kinases are activated to phosphorylate proteins such as GEFs;  3) Phosphorylation of 
GEFs lead to activation of Rac and Cdc42;  4)  Activated Rac1 and Cdc42 interact with 
several proteins involved in actin reorganization to from lamellipodia such as WAVE and 
WASP proteins, respectively;  5) WAVE and WASP proteins  bind to p21, a subunit of 
the Arp2/3 complex, to nucleate actin. Rac and Cdc42 can also interact with the Arp2/3 
complex independently through IRSp53, which may connect these signaling pathways; 6) 
The Arp2/3 complex polymerizes an array of branched actin in the at the leading edge of 
the migrating endothelial cell.  During this time, Rac and Cdc42 signaling inhibits actin 
depolymerization by inactivating cofilin, which severs actin filaments, through the 
effectors PAK and LIMK. (Model adapted from Ridley, TRENDS in Cell Bio, 2001 and 
Ridley, JCS, 2001) 
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Vascular permeability through ROS 
 
 The role of Rho GTPases in vascular permeability has been investigated for 
several years.  However, how these proteins induce permeability, especially downstream 
of VEGF signaling is understudied. It has been shown that RhoA and its effector Rho 
Kinase (ROCK/ROK) can induce actomyosin contractility of stress fibers to open gaps 
between endothelial cells, thus decreasing barrier function165.  Cdc42 has consistently 
been shown not to affect permeability, but it has been implicated in restoring the barrier 
integrity of adherens junctions through VE-cadherin in two different human endothelial 
cell types 24,166,167. However, the role of Rac1 in regulating endothelial barrier integrity 
remains controversial at best. Rac was first thought to enhance endothelial cell barrier 
function.  Work from Lampugnani et al. (2002) demonstrated that Rac was required for 
the assembly and maturation of endothelial cell-cell junctions and that Rac activity 
increased during junction formation168.    Another study showed that adenoviral 
overexpression of a dominant negative Rac (Rac17N) in HUVECs induced unstimulated 
permeability, again suggesting that normally Rac would protect barrier integrity. 
Conversely, this study also showed that Rac increased thrombin-induced permeability, 
thus implying that Rac can act in concert with Rho to synergize its permeability effects24. 
This result begs the question:  How does Rac induce permeability in response to stimuli 
such as VEGF?  Work by Eriksson et al. (2003) observed that Rac1 caused fenestrations 
between endothelial cells in response to VEGF, causing increased vascular permeability.  
The observed increase in permeability occurred downstream of VEGFR-2 in a PLCγ and 
eNOS-dependent manner169. However, a later study by Seebach and colleagues showed 
that Rac1 activated in response VEGF increased endothelial cell barrier function, whereas 
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a dominant negative Rac1 abolished these effects.  Interestingly, VE-cadherin and 
catenins at adherens junctions were tyrosine phosphorylated, which was previously 
characterized as a phenotype leading to junctional disassembly122,170.  Though there are 
many conflicting lines of evidence describing how Rac may be involved in VEGF-
induced endothelial cell permeability, one means may be the generation of reactive 
oxygen species in endothelial cells.   
 The term reactive oxygen species (ROS) refers to free radicals or free radical 
products generated by the mitochondria, nitric oxygen synthase (NOS), cytochrome 
p450, xanthine oxidase, and NADPH oxidase complex in endothelial cells.  The major 
free radical generated in endothelial cells is superoxide (O2-) that forms ionic bonds with 
other molecules to form hydrogen peroxide (H2O2).    As free radical products, these ROS 
play a critical role in physiological and pathological processes. Excessive levels of ROS 
can cause cell death due to oxidative stress and lead to many vascular pathologies such as 
atherosclerosis, diabetes, and hypertension. Yet, low to moderate levels of ROS 
generated by growth factor stimulation and hypoxia can mediate permeability, 
proliferation, and migration in endothelial cells, contributing to the initiation of 
angiogenesis in vivo29,171.   In endothelial cells, Rac-mediated ROS production has been 
shown to mediate tyrosine phosphorylation of MAPK in response to shear stress172. 
Interestingly, exogenous ROS in the form of H2O2 can upregulate VEGF expression and 
VEGFR-2 autophosphorylation in endothelial cells to stimulate actin reorganization173-
176.   
Signaling by ROS, also known as redox signaling, may be a key regulator in Rac-
induced permeability effects.  Although there are multiple sources of ROS in endothelial 
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cells, the NADPH oxidase complex is the major contributor.  Under basal conditions, 
NADPH oxidase continuously generates low levels of O2- .  However, this complex can 
produce more when activated in response to numerous stimuli including cytokines, shear 
stress, hypoxia and growth factors such as VEGF171.  Stimulation by VEGF increases 
ROS production through the activation of NADPH oxidase downstream of Rac1 in 
endothelial cells175-177.  NADPH oxidase is comprised of p22phox, p47phox, p67phox and a 
member of the NOX proteins (NOX1, NOX2, and NOX4), which are localized to the 
plasma membrane and activated in a Rac-dependent manner.  However, work by van 
Buul et al. (2006) only detected mRNA transcripts for NOX2 and NOX4, not NOX1, in 
HUVECs178.  It has been shown that NOX2, a key component of this complex, is 
activated by VEGF, yet the other proteins have not175,176.  Indirectly, VEGF signaling has 
been implicated in the translocation of Rac effector WAVE1 and p47phox to membrane 
ruffles and focal complexes84.  After upregulated O2- production, an enzyme called 
superoxide dismutase (SOD) captures these free radicals and reduces them to less toxic 
oxygen (O2) ions and H2O2 as a means of protecting the cell.  The most abundant SOD in 
endothelial cells, SOD2, is a target of VEGF and facilitates NADPH oxidase production 
of O2- in a feedback mechanism177.   
 The actual mechanism utilized by the Rac1-activated ROS production 
downstream of VEGF signaling to mediate endothelial cell behavior has been partially 
resolved.  Signaling by ROS can inactivate redox-sensitive protein tyrosine phosphatases 
(PTPs)27.  These PTPs including SHP-1, SHP-2, and high cell density-enhanced PTP1 
(DEP-1) are expressed in endothelial cells and associate with VEGFR-2 when activated7.  
Further, these phosphatases has been shown to attenuate or inhibit VEGFR-2 signaling to 
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block biological activities such as migration171. PTPs are inactivated when oxidized by 
ROS, but inactivation is reversible and can convert from inactive to active states easily.  
In addition to regulating phosphatase activity, ROS can activate p38 MAPK (often used 
as an indirect readout of ROS production) as well as Src and eNOS to affect endothelial 
cell responses29,171.  Moreover, there may be crosstalk between NADPH oxidase and 
eNOS in these pathways179.  A model of VEGF-stimulated ROS production is illustrated 
in Figure 1.6. 
The link between Rac-induced ROS production and proteins at cell-cell junctions 
has been an enigma.  The production of ROS may either activate tyrosine kinases or 
inactivate PTPs, which regulate the phosphorylation state of adhesion proteins at these 
junctions.  Signaling downstream of VEGFR-2 leads to phosphorylation of VE-cadherin 
and associating catenin proteins (β-catenin, p120catenin, plakoglobin/γ-catenin, and α-
catenin) on key tyrosine residues, which has been shown to induce permeability by 
relieving association with the actin cytoskeleton and loosening adherens junctions. In 
epithelial cells, specific residues on β-catenin (Tyr654) and p120catenin (Tyr217) were 
shown to mediate their association to E-Cadherin180,181.  Similar to VE-cadherin, Src may 
regulate tyrosine phosphorylation of these proteins28,181.   The specific tyrosine residues 
that are phosphorylated on catenin proteins in response to VEGF to facilitate VE-
cadherin interaction have not been delineated. The role of ROS in this pathway is evident 
in work by van Wetering and coworkers that observed ROS mediated loss of cell-cell 
adhesion in response to a constitutively active Rac1 mutant (RacV12) in HUVECs that 
was rescued when cells were treated with N-acetylcysteine (N-Ac), a scavenger of ROS.  
Further, this increase in tyrosine phosphorylation of VE-cadherin and α-catenin in 
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adherens junctions was inhibited by scavenging ROS with N-Ac29.  These findings 
challenge work previously published that stated Rac1 increases junctional integrity24,168.   
Work from the same group implicated that another tyrosine kinase, Pyk2, reduces cell-
cell adhesion by phosphorylating β-catenin downstream of Rac-induced ROS production, 
suggesting that multiple kinases may be coupling ROS to endothelial cell junctions30. 
Collectively, these studies illustrate a pathway by which the generation of ROS promotes 
tyrosine phosphorylation of adherens junction proteins resulting in elevated permeability.   
As described previously, the presence of PTPs counteracts kinase activity by 
dephosphorylating junctional proteins.  Phosphatases such as and SHP-1, SHP-2,  and 
DEP-1 influence VE-cadherin-catenin complex interactions and cell-cell junctions in 
tandem with VEGFR-2 signaling123,182-184.  VEGF-mediated oxidation of critical cysteine 
residues on these phosphatases through ROS lead to inactivation of many of these 
proteins.  Both SHP-1 and SHP-2 dephosphorylate VEGFR-2 and favor its 
internalization, which may permit the loosening of cell-cell junctions183,185.   However, 
adhesion of endothelial cells on collagen I inhibits VEGFR-2 signaling due to SHP-2 
dephosphorylation of the receptor186.   ROS production inactivates SHP-1 in endothelial 
cells after VEGF treatment; thereby, inhibiting MAPK signaling that may be required for 
proliferation187.  In confluent endothelial cell monolayers, SHP-2 is a target of ROS and 
promotes cell growth during contact inhibition when SHP-2 is in its inactive, oxidized 
state188.  Coincidently, DEP-1 was also found at cell-cell junctions of confluent 
monolayers and formed a complex with VEGFR-2 where it is in close proximity for 
dephosphorylation123.  Another endothelial cell-specific phosphatase, VE-PTP was not 
shown to associate with VEGFR-2 using a VE-PTP trapping mutant nor to 
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dephosphorylate VEGFR-2; thereby may not facilitate VEGFR-2-mediated junctional 
disassembly189.  Despite this biochemical data, in vivo studies in VE-ptp null mice display 
normal vasculogenesis, but defective angiogenesis and remodeling of capillaries in 
embryonic yolk sacs190,191.  However, it is unknown whether VEGF-induced tyrosine 
phosphorylation or dephosphorylation of adherens junction proteins is modulated by 
redox signaling via ROS to induce vascular permeability.  Now that we have described 
the role Rac1 plays downstream of VEGF signaling to regulate endothelial cell migration 
and permeability, we will explore how VEGF activates Rac1 through the aid of GEFs, 
particularly Rho family GEF Vav2. 
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Figure 1.6  Model of Reactive Oxygen Species (ROS) production by NADPH 
Oxidase in endothelial cells. 
This model illustrates how ROS production affects endothelial cell responses downstream 
of VEGF. VEGF via VEGFR-2 signaling activates small GTPase Rac1 facilitating its 
translocation to the plasma membrane where it interacts with components of the NADPH 
complex (p67phox, p47phox, p22, and NOX proteins).  This interaction results in increased 
cytosolic reactive oxygen species, namely superoxide (O2-).  Cytosolic and mitochondrial 
O2- are converted to hydrogen peroxide (H2O2) by superoxide dismutase (SOD).  
Antioxidants N-acetylcysteine (N-Ac) and catalase regulate the conversion of H2O2 back 
into water and oxygen molecules.  Increased levels of H2O2 effect endothelial cell in 
many ways. H2O2 can oxidize and inactivate protein tyrosine phosphatases (PTPs), which 
upregulates VEGFR-2 phosphorylation and subsequent continuous activation. H2O2 can 
also increased levels of p38 MAPK, Src, and endothelial nitrogen oxide synthase (eNOS) 
in the cytosol. Together, this pathways lead to redox signaling that affects endothelial cell 
responses such as permeability, migration, and proliferation.  (Model adapted from 
Ushio-Fukai, Cardiovascular Res, 2006) 
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Activation of Small GTPase Rac by Exchange Factor Vav2 
 
Like other Rho GTPases, Rac1 is activated upon the exchange and binding of 
GDP for GTP.   In a GTP-bound state, Rac1 undergoes a conformational change that 
allows it to interact with effector proteins.  GEFs catalyze and accelerate intrinsic GDP-
GTP exchange to activates Rac1, thus initiating its interactions with effectors.  Therefore, 
GEFs play a crucial role in Rac1 signaling to regulate the actin cytoskeleton. Vav 
proteins are one highly studied family of GEFs for Rho GTPases.  Vav proteins transduce 
signals from many cell-surface receptors to Rho GTPases. In addition, these proteins can 
act upon multiple Rho GTPases, namely RhoA, RhoB, RhoG, Rac1, and Cdc42192. This 
family is comprised of three known members in mammals (Vav1, Vav2, and Vav3), 
though Vav-like homologues have been identified in invertebrates and fish193.  These 
proteins have high sequence identities and structurally similar protein domains that allow 
them to possess both scaffolding and catalytic characteristics.  Vav1, the first isolated 
member of this family, is primarily expressed in hematopoietic cells, whereas Vav2 and 
Vav3 are more ubiquitously expressed in embryo and adult tissues. 
The first studies of Vav proteins, especially Vav1, either focused on their role in 
hematopoietic function because of their abundant expression in lymphoid cells or 
oncogenic potential in Ras-mediated transformation of non-hematopoietic cells such as 
NIH 3T3 fibroblasts.  Early studies showed that knockout Vav1 mice have defects in 
embryonic development as well as antigen-receptor-mediated B- and T-cell proliferation 
and differentiation194-196.  In particular, Vav1 is imperative for activating Rho GTPases in 
T cells during immune response.  Vav1 regulates Rac1- and Cdc42-mediated 
reorganization of the actin cytoskeleton to facilitate cell spreading and phagocytosis as 
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well as lipid raft clustering of T-cell receptor (TCR) and integrins during immunological 
synapse in T cells196. In non-hematopoietic cells, overexpression of wild-type Vav1 
induced minimal transformation of NIH3T3 fibroblasts, whereas removal of 65 residues 
in its N-terminus was sufficient to induce complete transformation, thus illustrating its 
ability to act as an onocogene197.  Since that time, Vav1 has been implicated in a 
multitude of processes in hematopoietic cells including apoptosis, cytotoxicity, and gene 
transcription196.  Interestingly, Vav1 also participates in platelet aggregation and 
spreading in response to thrombin196.  Similar studies have looked at the roles of Vav2 
and Vav3 in hematopoiesis and transformation. Mice deficient in Vav1 and Vav2 revealed 
a compensatory role for Vav2 in B-cell maturation, not in T-cells, whereas other studies 
demonstrated that Vav3 is involved in both B-cell receptor (BCR) and TCR downstream 
signaling198-201.  The importance of these proteins is evident in studies that revealed mice 
genetically lacking all Vav isoforms had defects in B- and T-cell development and 
dysregulated MAPK signaling, but no other maladies were identified outside of 
lymphocytes202. Moreover, studies have shown that both Vav2 and Vav3 can cause 
transformation and foci formation in NIH3T3 and HEK293T cells with the deletion of its 
N-terminus similar to other Vav1; though, Vav2 may also require two other protein 
domains for full oncogenic potential203,204.   
Besides their ability to transform cells to a cancer phenotype, Vav2 or Vav3 were 
not linked to any non-hematopoietic defects until recently. Two successive studies by 
Sauzeau and colleagues observed that mice deficient in Vav2 or Vav3 displayed 
tachycardia, hypertension, and aberrant cardiovascular remodeling, implying that these 
proteins are important for cardiovascular and renal homeostasis205,206.  These recent 
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observations suggest that both Vav2 and Vav3 may be important in the development and 
maintenance of blood vessels.  Yet, for the purpose of this discussion, we will focus on 
the prospective and novel role of Vav2 in endothelial cell behavior. A few examples of 
tissue expression, regulation, and function of Vav2 during physiological and pathological 
situations is illustrated in Table 1.2. 
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TABLE 1.2  Expression, Regulation, and Function of Vav2 
Cell 
Expression 
Upstream 
Receptors 
Biological 
Function 
Physiological 
Effects 
 Refs 
Physiological 
 
Hematopoietic 
 
 
 
Epithelial 
 
 
 
 
Endothelial 
 
 
 
 
Smooth Muscle 
 
 
Stromal 
 
 
Neuronal 
 
 
BCR 
TCR 
 
 
c-Met 
Integrins 
E-Cadherin 
 
 
P2Y2/VEGFR-2 
VEGFR-2 
Prostanoid 
EphR 
 
AT1 
 
 
EGFR 
PDGFR 
 
NGF-R 
Eph-R 
L1 
 
                
Maturation 
Antigen 
Recognition 
Proliferation 
 
Cell Scattering 
Cell Spreading 
Barrier Function 
 
Cell Migration 
Barrier Function 
 
 
Vascular 
Remodeling 
 
Cell Migration 
Cell Spreading 
 
Cell Migration 
 
 
 
 
Immune Response 
 
 
 
Cell Adhesion 
Junctional Integrity 
 
 
BV Formation 
Junctional Integrity 
 
 
 
CV Hemostasis 
SNS Regulation 
 
 
 
 
Neurite Outgrowth 
Axon Guidance 
Growth Cone 
Development 
 
 
 
198-200,202 
 
 
 
207-209 
 
 
115,210-212 
 
 
 
206 
 
 
158,213-216 
 
 
217-219 
Pathological 
 
Breast Cancer 
 
Ovarian Cancer
 
Mammary 
Tumor 
 
Head and Neck 
Carcinoma 
 
 
PRL-R 
 
CD44v3 
 
HER/Neu 
 
 
CD47 
 
 
Stat-5 Transcription 
 
Cell Migration 
 
Cell Migration 
 
 
Cell Migration 
 
 
Tumor Growth 
Cell Invasion 
Cell Metastasis 
 
 
 
220-223 
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Table 1.2  Expression, Regulation, and Function of Vav2 
This table highlights the known cell expression profile of Vav2 and receptors that have 
been shown to act upstream of Vav2 activity.  In addition, this table emphasizes Vav2’s 
biological and physiological consequences in response to upstream mediators. 
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Vav2 effects on exchange activity and cell morphology  
Like the other Vav proteins, Vav2 is promiscuous because it can exert its 
exchange activity on numerous Rho GTPases. However, the specificity of Vav2 
exchange activity on Rho GTPases was controversial during its early stages of 
characterization.  Initial in vitro studies using baculovirus-derived recombinant proteins 
demonstrated that Vav2 exhibited GEF activity on RhoA, RhoB, and RhoG, but not for 
Rac1 and Cdc42224. A second study observed that N-terminal truncated Vav2 mutant 
(ΔN-191 Vav2) activated Rac1, Cdc42, and RhoA in vitro with a comparable higher 
affinity for nucleotide exchange on Rac1 and Cdc42, which contrasted the results from 
the aforementioned study192. This paper also showed that cells transfected with wild-type 
Vav2 had increased levels of active Rac in vivo. Interestingly, both studies were 
performed in the same cell type (NIH-3T3 fibroblasts) and used similar methods of 
determining exchange activity. In that same year, Liu and Burridge (2002) reported that a 
truncated, constitutively active Vav2 mutant (Δ184N Vav2) elevated activity of RhoA, 
Cdc42, and Rac1 in vivo213.  Another group confirmed these results by showing co-
expression of RhoA, Rac1, and Cdc42 with Vav2 has contrasting effects on in vivo 
GTPase activation. In this work, Vav2 robustly activated Rac1, whereas Cdc42 activation 
was marginal and RhoA activation was detectable to an even lesser extent in three 
different cell types214. These varied characterizations of Vav2 GEF activity may reflect 
differences between in vitro and in vivo assays as well as specific factors that may control 
Vav2 activity in vivo such as subcellular localization and adaptor protein interactions. 
Beyond activating target Rho GTPases, the downstream effects of Vav2 on cell 
morphology were even more conflicting. Schuebel and colleagues (1998) initially 
 50
observed that stably expressed wild-type Vav2 resulted in the formation of abundant 
stress fibers, whereas transient overexpression of wild-type Vav2 caused lamellipodia 
and membrane ruffles, not stress fibers in NIH3T3 cells224.    Another group also 
observed that transient expression of constitutive active Vav2 in NIH3T3 cells created 
more lamellipodia and membrane ruffles than untransfected cells. In contrast to Schuebel 
and colleagues, this group also published that transiently transfected cells displayed well-
developed stress fibers192.  These results were substantiated when it was published that 
cells expressing N-terminus truncated, activated Vav2 had extensive lamellipodia and 
membrane ruffling as well as prominent stress fibers in CHO cells213. Subsequently, two 
different groups showed that cells transiently transfected with wild-type Vav2 displayed 
extensive lamellipodia and/or membrane ruffling with little effects on stress fiber 
formation, suggesting that Vav2 was acting more strongly on Rac than RhoA158,214.  Of 
note, Marignani and Carpenter also showed that Vav2 was not essential for lamellipodia 
formation in response to EGF and PDGF, implicating other GEFs activating Rac1 
donstream EGF and PDGF214.  The morphological differences seen between stable and 
transient expression of Vav2 may result from contrasting levels of GTPase activation in 
vivo.  In addition, the conflicting observations seen with wild-type versus constitutively 
active Vav2 may suggest that enhanced Vav2 activity preferentially acts upon Rac1 in 
vivo.  Despite the controversy of Vav2’s influence on stress fiber formation, its role in 
lamellipodia and membrane ruffle formation is compelling. It is generally accepted that 
Vav2 plays a strong role in Rac1-mediated cell migration. 
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Structure of Vav2 
 
The structure of Vav2 illustrates its role as a signal transducer in multiple 
pathways.  Within its N-terminus, Vav2 has critical protein domains important for its 
activation. This region is comprised of a calponin homology (CH) domain, which is 
found in many actin-binding proteins such as α-actinin, and an acidic amino acid-rich 
(AD) domain that is normally found in transcription factors.  The acidic domain contains 
three tyrosine residues that are important for regulation of Vav2 exchange activity. 
Together, these domains negatively regulate Vav2 activity by folding back onto the 
adjacent catalytic Dbl homology (DH) domain, thus forming an autoinhibitory loop that 
sterically prevents activation.  In this “closed” configuration, Vav2 is unable to interact 
with its target to confer its exchange activity. Phosphorylation of a tyrosine residue in the 
acidic domain relieves this inhibition, thus creating an “open” conformation that allows 
stable association with Rac1225.  The effect of tyrosine phosphorylation on Vav2 
exchange activity will be discussed in a later section.  It has been shown that deletions or 
point mutations of the CH and AD domains in the N-terminus of Vav2, like Vav1 and 
Vav3, increased exchange activity on Rho GTPases, inducing changes in cell 
morphology and cellular effects such as transformation213,224,226. 
Vav2 is a one of 69 members of the Dbl homology (DH) family of Rho GEFs, 
including Rac-specific GEFs Sos1 and β-PIX.  These proteins have a ~200-residue DH 
and a tandem ~100-residue pleckstrin homology (PH) domain that are functionally 
interdependent.  The DH domain facilitates binding to target GTPases and catalyzes 
exchange activity.  When a basic lysine of the DH domain of Vav2 was mutated, it 
prevents Rac1 activation and lamellipodia formation in NIH3T3 cells214.  The associated 
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PH domain binds phosphoinositides, products of PI3K in the plasma membrane. This 
domain may serve two functions in Dbl proteins by promoting membrane targeting for 
appropriate localization in the cell and regulating of DH domain catalytic function. 
Although mutations in the PH domain of Vav1 and Vav3 did not inhibit exchange 
activity, the PH domain of Vav2 is necessary for its function226,227. Several studies have 
examined the importance of this domain in Vav2 exchange activity and subsequent 
cellular effects.  A study by Booden et al. (2000) showed that mutations in the PH 
domain of Vav2 impaired signaling and membrane association as well as transformation 
ability, but did not affect Rac1 activation203.   In contrast, another group demonstrated 
that a point mutation of a conserved arginine residue to glycine (Arg425Gly) in the PH 
domain, which is unable to bind PIP3, did not activate Rac or induce lamellipodia 
formation, suggesting that the PH domain is necessary for Vav2 activity214.  In EGF-
stimulated cells, a  similar point mutation (Arg425Cys) in this domain also inhibited its 
GEF activity on Rac1228.  The specific role of the PH domain in PI3K-regulated 
membrane targeting will be examined later. 
 C-terminal domains in Vav2 promote its interactions with other proteins.  
Adjacent to the PH domain is the cysteine-rich domain (CRD) and a single Src homology 
2 (SH2) domain flanked by two SH3 domains. The CRD domain, which is also known as 
the C1 domain, promotes membrane association of protein kinase C (PKC) and other 
signaling proteins by binding lipid membranes. Truncation of the CRD attenuates Vav2 
signaling and transformation by impairing DH domain catalytic activity, but does not 
affect membrane targeting of the PH domain as implied in previous studies with Vav1 
and Vav3203,226,229.  Interestingly, the unique CRD domain of Vav2 may preferentially 
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increase its binding and exchange affinity for Rac1 in comparison to RhoA and Cdc42230.  
The presence of the SH3-SH2-SH3 cassette illustrates how Vav2 can act as an adaptor 
protein with multiple functions.  Although distinct Vav2 binding partners have not been 
fully characterized in non-hematopoietic cells, this C-terminus region may promote 
binding of adaptor protein Shc, Src, SHP-2, PTP-PEST, and VE-cadherin based on likely 
protein interactions described by several groups115,209,231-233.  One unconventional finding 
by Tamas and coworkers (2001) reported that Vav2 can target to the plasma membrane 
through its SH2 domain, thereby causing tyrosine phosphorylation and activation of Vav2 
after EGF stimulation234.  In later work, this group observed that the SH2 domain of 
Vav2 can directly bind to two distinct autophosphorylation sites (Tyr992 and Tyr1148) of 
the EGFR to stimulate direct phosphorylation of N-terminal tyrosine residues228. A 
similar mechanism has not been observed with other RTKs such as VEGFR-2.  In 
contrast, it has been shown that the C-terminal region of Vav2 acts as a dominant 
negative in EGF-induced Rac1 activation213.  Collectively, these respective domains 
serve important roles in Vav2 function in response to receptor signaling.  A schematic of 
Vav2, Sos1 and β-PIX protein domains is illustrated in Figure 1.7. 
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Figure 1.7  Model of Rac GEF protein domains. 
This model shows the different protein domains of Rac GEFs Vav2, Sos1, and β-PIX, 
which were investigated in this research.  This full length proteins contain several 
domains important for GEF activity, membrane localization, and regulation.  The 
domains in Vav2 include an amino terminal calponin homology domain for actin binding, 
acidic domain, Dbl homology domain (DH) for GEF activity, Pleckstrin homology 
domain (PH) and cysteine–rich domain (CRD)/C1 domain for membrane binding, SH3 
and SH2 domains in the carboxyl tail for protein interactions.  Vav2 also has three key 
tyrosine residues in its amino terminus (Y142, Y159, and Y172) that mediate protein 
conformation and R425 in its PH domain to regulate membrane targeting. Sos1 contains 
multiple GEF activity domains (DH, Ras GEFN and Ras GEF) because of its ability to 
activate both Rho and Ras proteins as well as a critical R459 residue in its PH domain is 
important for membrane localization.  β-PIX contains many of the same domains, but its 
PH domain is thought to be essential for its regulation via PIP2 binding on the plasma 
membrane, which activates GDP-GTP exchange. β-Pix also has a C-terminal coiled-coil 
domain that promote protein-protein interactions through dimerization. 
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Regulation of Vav2 
Vav2 can transduce signaling from diverse several cell surface receptors in non-
hematopoietic cells, especially receptor tyrosine kinases (RTKs).  These RTKs include 
the platelet derived growth factor receptor (PDGFR), epidermal growth factor (EGFR), 
and ephrin receptors (EphR)158,213,218,228.  Two studies have explored that Vav2 activation 
downstream of VEGF signaling115,211.  In most cases, signaling from these RTKs can 
cause two regulatory mechanisms to occur on Vav2, transient tyrosine phosphorylation or 
translocation to the plasma membrane.  Each of these mechanisms regulates the exchange 
activity, protein interactions, and localization of Vav2. This next section will describe the 
two processes the regulate Vav2 exchange activity, beginning with tyrosine 
phosphorylation. 
Phosphorylation of crucial tyrosine residues can either promote final activation of 
latent enzymatic activity or make it possible for complexes to form between Vav2 and 
interacting proteins.  Vav2 has three conserved tyrosine residues in the acidic domain of 
the N-terminus that affect exchange activity (Tyr142, Tyr159, and Tyr172).  Tamas and 
colleagues showed that single and combinatorial point mutations of these tyrosine 
residues to phenylalanine (Tyr143Phe, Tyr159Phe, and Tyr172Phe), thus making these 
residues unable to be phosphorylated, were still capable of activating Rac after EGF 
stimulation228.  Despite this result, Tyr172 has been most studied for its regulation of 
Vav2 activity. Phosphorylation of this residue disrupts an autoinhibitory interaction with 
the N-terminus and the DH domain to change Vav2 to an “open” conformation that is 
available for GTPase binding and exchange activity. This mechanism to relieve 
autoinhibition is also found in Vav1 and Vav3 because these proteins have corresponding 
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tyrosine residues in the acidic domain of their N-termini, Tyr174 in Vav1 and Tyr173 in 
Vav3204,225,228.  Direct or indirect association with RTK signaling mediates tyrosine 
phosphorylation of Vav2.  In neurons, when Vav2 is phosphorylated on Tyr172 it 
interacts with the intercellular domain of the Ephrin receptor (EphR).  This interaction 
induces endocytosis of the ephrin-EphR complex to downregulate its signaling and 
inhibit axon guidance218.  Vav2 is also tyrosine phosphorylated in response to PDGF and 
EGF, thus activating Rac1 to mediate cell migration and adhesion213,215,224.  To date, two 
published studies have implicated Vav2 downstream of VEGFR-2 signaling to activate 
Rho GTPases.  UTP nucleotide stimulation of a chimeric VEGFR-2/P2Y2R receptor 
tyrosine phosphorylates Vav2 and activates Rac1 and RhoA , but not Cdc42 to mediate 
vascular cell adhesion molecule-1 (VCAM-1) expression in endothelial cells211.  
However, this study did not examine Vav2 activity in response to endogenous, wild-type 
VEGFR-2.  Another study showed that VEGF signaling, specifically through VEGFR-2, 
tyrosine phosphorylates Vav2 to activate Rac1; in addition, this event was required for 
VE-cadherin internalization during endothelial cell permeability115.  In these respective 
works, neither group investigated whether phosphorylation occurred specifically on 
Tyr172.  The tyrosine kinase Src has been highly-studied as an upstream mediator of 
Vav2 phosphorylation, though there is one study that suggests Vav2 directly binds to the 
EGF receptor to become phosphorylated115,208,209,214,228. Interestingly, tyrosine 
phosphorylation of Vav2 on those three N-terminal residues may have contrasting 
regulatory effects on Rac activity193,213,235. Lastly, phosphorylation of C-terminal tyrosine 
residues in the SH3-SH2-SH3 domains may be important for protein-protein interaction 
and localization to the plasma membrane, but this hypothesis requires further study in 
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non-hematopoietic cells, especially endothelial cells193,234. 
Although tyrosine phosphorylation is an important regulatory mechanism, 
membrane targeting through the activation of PI3K may be equally required for Vav2 
GEF activity.  For Vav1 and Vav3, binding to phosphoinositide products of PI3K, PIP2 
and PIP3, via their respective PH domains stimulates exchange activity.  For Vav1, 
however, pretreatment of cell with PI3K inhibitor wortmannin partially blocks Rac 
activation and lamellipodia formation236.  Notably, wortmannin treatment did not affect 
Vav2-dependent Rac1 activation or lamellipodia formation214.  This result suggests that 
possibly another lipid kinase such as phosphoinositide 4-Kinase (PI4K) or 
phosphoinositide 5-Kinase (PI5K) may compensate for PI3K function in the presence of 
wortmannin by producing lipid substrates that the PH domain of Vav2 can bind.  Another 
study showed that treatment of cells with more specific PI3K inhibitor LY294002 prior to 
EGF treatment markedly reduced Vav2 exchange activity on Rac1.  In addition, 
LY294002 did not decrease Vav2 tyrosine phosphorylation in response to EGF, implying 
that membrane targeting to lipid products of PI3K does not affect EGF-mediated Vav2 
phosphorylation.  The contradiction of results observed with these two PI3K inhibitors 
may address a caveat of using wortmannin, which has been characterized as a non-
specific and weak inhibitor of PI3K function compared to LY294002228.  Work by 
Brachmann et al. (2005) reported that mouse embryonic fibroblasts (MEFs) deficient in 
the subunits that comprise PI3K (p85α/p55α/p85β/p55β), which results in a loss of PI3K 
function, did not induce membrane ruffing in response to PDGF; however, 
overexpression of wild-type Vav2 in these cells rescued the phenotype237. Again, these 
data propose that other lipid kinases may have redundant roles in the absence of PI3K to 
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stimulate Vav2 activity.  Taken together, PI3K facilitates in modulating Vav2 function, 
but the role of other lipid kinases in the regulation of Vav2 exchange activity and cellular 
effects needs to be investigated. 
This introductory chapter has provided background on several proteins discussed 
in this dissertation, while highlighting the proteins that will be studied extensively with 
respect to endothelial cell behavior. Additionally, this chapter indicates the significance 
of this work by emphasizing the unanswered or poorly characterized questions 
concerning the roles of the proteins in these biological processes downstream of VEGF 
signaling.  The goal of this dissertation was to elucidate how VEGFR-2 signaling to Vav2 
induces Rac1 activation and subsequent cell migration, and to determine if VEGFR-2 
signals through ROS to stimulate vascular permeability. The achievement of this goal 
begins in the following chapter, which will focus on understanding the mechanisms of 
VEGF-induced Rac1 activation during endothelial cell migration.  The subsequent 
chapter will investigate VEGFR-2 signaling to ROS as a means of promoting decreased 
endothelial barrier function via adherens junctions. A final chapter will discuss the future 
perspectives of this research and its place in endothelial cell biology. 
 
  
 
CHAPTER TWO 
THE GUANINE NUCLEOTIDE EXCHANGE FACTOR VAV2 REGULATES 
VEGF-INDUCED RAC1 ACTIVATION IN ENDOTHELIAL CELLS 
 
ABSTRACT 
 
Vascular endothelial growth factor (VEGF) signaling is critical for both normal and 
disease-associated vascular development. Dysregulated VEGF signaling has been 
implicated in ischemic stroke, tumor angiogenesis, and many other vascular diseases. 
VEGF signals through several effectors, including the Rho family of small GTPases. As a 
member of this family, Rac1 promotes VEGF-induced endothelial cell migration by 
stimulating the formation of lamellipodia and membrane ruffles. To form these 
membrane protrusions, Rac1 is activated by guanine nucleotide exchange factors (GEFs) 
that catalyze the exchange of GDP for GTP.  The goal of this study was to identify the 
GEF responsible for activating Rac1 in response to VEGF stimulation.  
We have found that VEGF stimulates biphasic activation of Rac1 and for these 
studies we focused on the peak of activation that occurs at 30 min.  Inhibition of VEGFR-
2 signaling blocks VEGF-induced Rac1 activation.  Using a Rac1 nucleotide-free mutant 
(G15ARac1), which has a high affinity for binding activated GEFs, we show that the Rac 
GEF Vav2 associates with G15ARac1 after VEGF stimulation. Additionally, we show 
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that depleting endothelial cells of endogenous Vav2 with siRNA prevents VEGF-induced 
Rac1 activation. Moreover, Vav2 is tyrosine phosphorylated upon VEGF treatment, 
which temporally correlates with Rac1 activation and requires VEGFR-2 signaling and 
Src kinase activity. Finally, we show that depressing Vav2 expression by siRNA impairs 
VEGF-induced endothelial cell migration. Taken together, our results provide evidence 
that Vav2 acts downstream of VEGF to activate Rac1.   
 
INTRODUCTION 
 
Angiogenesis, the sprouting of new blood vessels from a pre-existing vascular 
network, occurs in many physiological and pathological conditions.  This process is 
initiated by the migration of endothelial cells in response to chemotactic agents such as 
vascular endothelial growth factor (VEGF).  VEGF is a soluble glycoprotein that 
promotes wound healing and blood vessel formation during specific biological processes 
such as pregnancy 1.  Though VEGF signaling is required for normal vascularization, 
aberrant signaling is linked to many diseases because of its ability to stimulate 
inappropriate cell proliferation, motility, and permeability. For example, in tumor 
angiogenesis, VEGF enhances tumor growth by inducing the migration and organization 
of surrounding endothelial cells into nascent blood vessels 1,6.  
Previous work has shown that VEGF signaling induces lamellipodia formation 
and increases the migration of endothelial cells 23,143,151. During this process, VEGF 
elicits its biological effects such as migration through VEGF receptor-2 (VEGFR-2), a 
member of the VEGF family of receptor tyrosine kinases found in endothelial cells 103.     
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  VEGF-induced endothelial cell migration is mediated by many signaling 
molecules including the Rho family of small GTPases. Rho GTPases transduce signals 
from extracellular stimuli to cause changes in cell behavior 127.  The best characterized 
members of the family, RhoA, Cdc42, and Rac1 affect many cellular processes required 
for growth and survival including cytoskeletal organization, cell morphology, and 
adhesion.  Of these GTPases, active Rac1 has been shown to stimulate cell migration by 
inducing lamellipodia formation. The effects of VEGF on endothelial cell motility are 
inhibited when Rac1 activity is perturbed 23,  suggesting that VEGF mediates actin 
remodeling through Rac1.    
Like other Rho GTPases, Rac1 acts as a molecular switch that cycles from an 
inactive GDP-bound state to an active GTP-bound state. Since Rac1 has an intrinsically 
low rate of GDP-GTP cycling, this process is promoted by guanine nucleotide exchange 
factors (GEFs) 126,238-240. GEFs often couple signaling pathways that involve the 
activation of cell surface receptors such as integrins and growth factor receptors to Rho 
GTPases.  In this study, we asked which exchange factor mediates Rac1 activity, 
downstream of VEGF signaling in endothelial cells and how its activity is regulated by 
VEGF.    
 
MATERIALS AND METHODS 
 
Cell culture - Pooled human umbilical vein endothelial cells (HUVECs) and human 
dermal microvascular endothelial cells (HMVEC-d) were obtained from Cambrex (East 
Rutherford, NJ) and grown in Clonetics EGM-2 or EGM-2-MV (for HMVEC-d) media 
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according to manufacturer’s instructions at 37°C and 10% CO2.  Cells were used between 
passages 3-6.  COS7 cells were grown in Dulbecco's modified Eagles medium (Sigma, 
St. Louis, MO) containing 10% fetal bovine serum (Sigma) and 
penicillin/streptomycin/fungizone (Invitrogen, Carlsbad, CA). Jurkat T cells were grown 
in RPMI 1640 media supplemented with 10% fetal calf serum (BioWhittaker, Rockland, 
ME).  
Antibodies and pharmacological reagents - Vav2 rabbit antiserum was generated 
previously and used as previously described 213. Vav2 rabbit polyclonal antibody (pAb) 
used for GST-G15ARac1 pulldown was obtained from Zymed (San Francisco, CA). 
Vav2 monoclonal antibody (mAb) was purchased from Babraham Bioscience 
Technologies (London, England). Anti-phosphotyrosine (pY20), Rac1, Cdc42, and Sos1 
mAbs were purchased from BD Transduction Laboratories (San Jose, CA). Anti-
phosphotyrosine (pY99) mAb, VEGF-1 pAb, RhoA mAb, β-PIX goat-pAb, and phospho-
Vav2 (pY172) rabbit-pAb were obtained from Santa Cruz Biotechnology (Santa Cruz, 
CA). Vav3 pAb, Src mAb and cortactin (clone 4F11) mAb was obtained from Upstate 
Biotechnology (Lake Placid, NY).  Vav1, VEGF-2 and VEGF-3 pAbs were purchased 
from Cell Signaling Technology. Phospho-Src (pY418) rabbit-pAb was purchased from 
Biosource (Camarillo, CA). Recombinant human VEGF165 was purchased from R&D 
Systems (Minneapolis, MN). VEGFR-2 inhibitors SU1498 and ZM323881, human α-
thrombin, Src inhibitors PP2 and SU6656, and inactive Src compound PP3 were 
purchased from Calbiochem (San Diego, CA).  Glutathione-Sepharose was purchased 
from Amersham Biosciences (Uppsala, Sweden).  
siRNA transfection - HUVECs were transfected at 90-100% confluency with the siRNA 
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oligos indicated in each experiment according to the manufacturer’s protocol using 
RNAifect Transfection Reagent (Qiagen, Valencia, CA).  After the delivery of the 2.5 μg 
for HUVECs and 5.0 μg for HMVEC-d siRNA oligos for 4 h, the transfection medium 
was replaced with fresh EGM-2 media for 24-36 h. Vav2-specific siRNA oligos against 
the human sequence were as follows: 5’ - UCACAGAGGCCAAGAAAUUUU - 3’ and 
5’ - AAUUUCUUGGCCUCUGUGAUU -3’. VEGFR-2 (KDR)-specific siRNA oligos 
against the human sequence were as follows: 5’- GGAAAUCUCUUGCAAGCUAUU - 
3’ and 5’ – UAGCUUGCAAGAGAUUUCCUU -3’.  Rac1-specific siRNA oligos 
against the human sequence  were as follows: 5’ - GUUCUUAAUUUGCUUUUCC - 3’ 
and 5’ - GGAAAAGCAAUUAAGAAC -3’ and were used at 20 nM as  described by 
Deroanne et al 241. siGLO, a non-specific siRNA oligo with a fluorescent rhodamine tag, 
was used as a control (Dharmacon, Chicago, IL). 
Immunoprecipitation and immunoblotting - For immunoprecipitation, HUVECs were 
starved in serum-free Optimem media for 1 h at 37°C under 10% CO2. Cells were then 
pretreated with specific VEGFR-2 inhibitors (50 μM SU1498 and 10 nM ZM323881) or 
Src inhibitors (30 μM PP2 or PP3, the latter being an inactive control) for 30 min at 
37°C.  Subsequently, cells were rinsed with PBS and treated with 10 ng/mL VEGF165 for 
the time specified. Cells were washed in cold PBS prior to scraping into modified ice-
cold RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% Triton X-100, 0.25% 
deoxycholate (DOC), 1.5 mM  MgCl2, 1 mM EGTA,  1 mM  phenylmethylsulfonyl 
fluoride (PMSF),  10 mM NaF,  10 mM pervanadate, 10 μg/mL  leupeptin,  10 μg/mL 
aprotinin) on ice.  Lysates were clarified by centrifugation at 16,000 x g for 10 min, 
precleared with protein A- or protein G-Sepharose beads for 30 min, and then incubated 
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with antibody and beads for 2 h at 4°C.  The beads were washed three times in RIPA 
buffer and bound proteins were eluted with SDS sample buffer. 
For immunoblotting, cells were washed in cold PBS and scraped into general lysis 
buffer (50 mM Tris-HCL, pH 7.6,  150 mM NaCl, 1% Triton X-100, 0.25% DOC, 2 mM 
EGTA,  1 mM  PMSF, 10 μg/mL  leupeptin,  10 μg/mL aprotinin).  Cells were lysed on 
ice and clarified by centrifugation.  For both techniques, protein concentrations were 
determined using detergent-compatible (DC) protein assay kit (Bio-Rad, Hercules, CA) 
according to the manufacturer’s instructions.  Equal amounts of total protein were 
denatured in SDS sample buffer, run on 10% SDS-polyacrylamide gels and transferred to 
Immobilon-P membrane. Blots were probed with primary antibody and then horseradish 
peroxidase-conjugated secondary antibody, visualized by enhanced chemiluminescence 
according to the manufacturer’s instructions. 
Chemotaxis assay - To assess the migratory behavior of endothelial cells transfected with 
Vav2 siRNA, chemotaxis assays were performed using Transwell polycarbonate filters 
(6.5-mm diameter, 8-μm pore size) (Costar, Acton, MA).  The top and bottom surfaces of 
the filters were coated with 10 μg/mL fibronectin in PBS overnight at 4°C.  After 
overnight incubation, 10 ng/mL VEGF165   in serum-free Optimem media was added to 
the lower chamber where indicated.   Equal amounts of Vav2 siRNA transfected cells 
(105) in serum-free Optimem media were added to the upper chamber and allowed to 
migrate for 4 h at 37°C. After 4 h, migrated cells were rinsed, fixed, stained with Hoechst 
33342 (Molecular Probes, Eugene, OR) and the number of cells that migrated to the other 
side of the filter were counted.  At least three fields per filter were counted using 
fluorescent microscopy. 
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GTPase activation assays - The GTPase activity of RhoA, Rac1, and Cdc42 was 
measured as previously described 242 with some modifications. Cells were rinsed with 
cold PBS and lysed in RIPA buffer as described. Lysates were cleared by centrifugation 
and protein concentration was measured. Equal amounts of protein (400-600 μg) were 
incubated with 50 μg GST fusion protein of Rho-binding domain of Rhotekin (GST-
RBD) or GST fusion protein of CRIB-binding domain of PAK (GST-PBD) bound to 
glutathione-Sepharose beads for 30 min at 4°C.   Active RhoA was precipitated with 
GST-RBD and active Rac1 and Cdc42 were precipitated with GST-PBD.  Beads were 
washed three times in buffer (50 mM Tris-HCl, pH 7.6, 500 mM NaCl, 1% Triton X-100, 
0.5 mM MgCl2, 1 mM  PMSF,   10 μg/mL  leupeptin,  10 μg/mL aprotinin) and 
associated proteins were eluted with sample buffer.  The amount of active RhoA, Rac1, 
and Cdc42 was then analyzed by immunoblotting and quantified by densitometric 
analysis using ImageJ software (NIH). 
Precipitation of Activated GEFs with Recombinant Rac1 Protein - To perform the 
pulldown assay with nucleotide-free Rac1 mutant (G15ARac1), HUVECs were lysed and 
processed as described in Garcia-Mata et al. 243.  Briefly, cells were lysed in a buffer 
consisting of 1% Triton X-100, 20 mM HEPES, pH 7.4, 150 mM NaCl, 5 mM MgCl2, 
and protease inhibitors. Lysates were cleared by centrifugation at 16,000 × g for 10 min. 
Equal amounts of protein (400-600 µg) were incubated at 4 °C for 60 min with 20 µg of 
GST or GST fusion proteins containing nucleotide-free Rac1 protein (G15ARac1) bound 
to glutathione-Sepharose. After 1 h of incubation, the beads were washed 4 times with 
lysis buffer. Samples were immunoblotted using antibodies against Vav2, Sos1 and β-
PIX. Membranes were also stained with Ponceau S prior to immunoblotting to confirm 
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that similar amounts of fusion proteins were used in all experiments.  
Scratch wound migration assays- HUVEC monolayers were grown on growth factor-
reduced Matrigel (BD Biosciences, San Jose, CA) for 48 h in glass-bottomed dishes 
(MatTek Corporation, Ashland, MA). Cells were starved for 1 h in serum-free Optimem 
media prior to the experiment. The monolayer was scratch-wounded with a pipet tip 
(Fisher Scientific, Suwanee, GA) and then washed to remove debris.  Cells were allowed 
to migrate for 48 h with images collected at desired time points. In both assays, images 
were obtained using a 10x objective on a Zeiss Axiovert microscope (Zeiss, Thornwood, 
NY) and analyzed using MetaMorph Imaging software (Universal Imaging Corp., West 
Chester, PA). 
Statistical Analysis - Statistical analysis was calculated using either Student’s t-test or 2-
way analysis of variance (ANOVA) where indicated.   
 
RESULTS 
 
VEGF activates Rac1 through VEGFR-2 in endothelial cells - We measured Rac1 
activity by using GST-PBD to pulldown GTP-Rac.  Work by Zeng et al. showed a rapid 
and transient increase in Rac1 activity around 5 min of VEGF treatment 86.  In 
preliminary work, we confirmed these results and found that there is a peak of Rac 
activity at 1-5 min which then declines. Extending the time course, we have found that 
there is a second peak of Rac activity that reaches a maximum 30 min after VEGF 
stimulation in both HUVECs and HMVEC-d (Fig. 2.1).  VEGF has also been shown to 
activate other small GTPases 86. We found that RhoA transiently becomes activated 5-15 
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min after VEGF treatment. This data confirmed work by other groups 26,144 that 
demonstrated a rapid and transient increase of RhoA activity in the first few minutes after 
VEGF treatment.  Cdc42 was also activated 5-15 min after stimulation with VEGF; this 
activity declined and elevated again around 60 min. The activation of RhoA and Cdc42 
decreased at 30 min and thus, do not correlate with the second peak of Rac activity (Fig. 
2.2).  In this study, we have focused on this second peak of Rac activity.   
VEGF functions are mediated  by three VEGF receptors (VEGFR-1, VEGFR-2, 
and VEGFR-3) expressed in HUVECs, but previous work has shown that the VEGFR-2 
is the main receptor responsible for processes such as cell migration 19,103,244,245.  To 
examine the role of this receptor in VEGF signaling to Rac1, we first used two 
structurally different but selective VEGFR-2 inhibitors, SU1498 and ZM323881.  Both 
inhibitors blocked VEGF-induced Rac1 activation at 30 min (Fig. 2.3A). Using siRNA 
against VEGFR-2, we successfully depleted VEGFR-2 expression in HUVECs, whereas 
VEGFR-1, VEGFR-3, and β-actin protein expression were not affected (Fig. 2.3B).  
VEGF-induced Rac1 activation was inhibited when VEGFR-2 expression was depleted 
by siRNA targeting (Fig. 2.3C).    Taken together, these results indicate that expression 
and activation of VEGFR-2 is required to mediate VEGF-induced Rac1 activation at 30 
min. 
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Figure 2.1  VEGF activates Rac1 in endothelial cells.   
 
HUVECs (top panels) or HMVEC-d (bottom panels) were serum starved for 1 h and 
treated with 10 ng/mL VEGF for the specified times and subsequently assayed for Rac1 
activity as described in Materials and Methods. The upper left panel shows Rac-GTP 
levels after VEGF treatment. The lower left panel shows total Rac1 levels. The histogram 
on the right shows quantification of the fold increase in Rac1 activity after VEGF 
stimulation in four independent experiments.   
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Figure 2.2  VEGF activates RhoA and Cdc42 in endothelial cells.   
 
HUVECs were serum starved for 1 h and treated with 10 ng/mL VEGF for the specified 
times and subsequently assayed for RhoA or Cdc42 activity as described in Materials and 
Methods. The upper left panel shows GTP levels of RhoA or Cdc42 after VEGF 
treatment. The lower left panel shows total levels of RhoA or Cdc42 expression. The 
histogram on the right shows quantification of the Rho-GTP or Cdc42-GTP levels after 
VEGF stimulation in four independent experiments. 
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Figure 2.3  Inhibition of VEGFR-2 signaling blocks VEGF-induced Rac1 activation.   
 
(A) Pharmacological VEGFR-2 inhibitors inhibit Rac1 activation by VEGF.  Cells were 
pretreated with either 50 μM SU1498 or 10 nM ZM323881 (VEGFR-2 inhibitors) for 30 
min at 37°C, followed by VEGF treatment for 30 min. Untreated (un) denotes cells not 
treated with VEGF.  The upper left panel shows that both inhibitors blocked Rac1 
activity at 30 min. The lower left panel shows equal protein loading of total Rac1. The 
histogram on the right shows quantification of Rac1 activation.  (B)  Knockdown of 
VEGFR-2 protein expression by siRNA.   HUVECs were transfected with either siGLO, 
a non-specific control siRNA oligo, or VEGFR-2-specific siRNA oligos as described in 
Materials and Methods. After 24 h, the cells were serum-starved for 1 h, treated with 
VEGF for 30 min and assayed for active Rac1.   Quantification of protein expression is 
shown in the histogram on the right (n = 3; **p < 0.01). (C) VEGFR-2-specific siRNA 
blocks Rac1 activity after VEGF stimulation.  HUVECs were assayed 24 h after 
transfection with VEGFR-2-specific siRNA as described in Materials and Methods.  The 
upper left panel shows VEGF-induced Rac1 activity is decreased in VEGFR-2 siRNA-
transfected cells compared to control cells.  The middle left panel confirms equal levels 
of total Rac1, and the lower left panel shows levels of VEGFR-2 expression following 
siRNA treatment. The histogram on the right represents the average Rac1 activation 
relative to total Rac1 levels in four independent experiments (n = 4; *p < 0.05 by 2-way 
ANOVA). 
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Exchange factor Vav2 couples VEGF signaling to Rac1 – It has been shown that several 
GEFs activate Rac1 in response to EGF and PDGF signaling 213,246-248.  To determine 
which exchange factors activate Rac1 downstream of VEGF, we first investigated the 
endogenous expression of candidate Rac1 GEFs in endothelial cells.  We identified Vav2, 
β-PIX and Sos-1 in HUVECs by western blotting (Fig. 2.4A).  Vav2 is a member of a 
family of closely related GEFs and we looked for the presence of Vav1 and Vav3 as well.  
Vav1 was not detected, consistent with its reported distribution being restricted to 
hematopoietic cells.  With Vav3, a weakly cross-reacting band was detected migrating 
slightly faster than the corresponding band detected in COS7 cells.  However, we did not 
detect the presence of Vav3 mRNA by RT-PCR in HUVECs.  Interestingly, in HMVEC-
d cells, we did detect low levels of Vav3 both by western blotting (Fig. 2.4B) and by RT-
PCR.   
In order to determine which GEF might be involved in Rac1 activation 
downstream from VEGF stimulation of HUVECs, we used nucleotide-free Rac1 in a 
pulldown strategy. This technique is based on the concept that GEFs bind small GTPases 
with high affinity when the GTPase is in a transitional nucleotide-free state 243,249.  As 
such, the nucleotide-free Rac1 mutant G15ARac1 has higher affinity for binding active 
GEFs, and our laboratory has used this mutant previously to bind and identify active 
GEFs 243.  Using a GST fusion protein of the G15ARac1 mutant, we found that 30 min 
VEGF treatment increased the association of Vav2 with G15ARac1.  Conversely, when 
we inhibited VEGFR-2 signaling with SU1498, VEGF treatment did not stimulate the 
interaction between Vav2 and G15ARac1 (Fig. 2.5A). G15ARac1 failed to pull down 
Sos1 after VEGF treatment, suggesting that Sos1 is not involved in VEGF-induced 
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signaling at this time point in endothelial cells. Low levels of β-PIX were detected 
binding to the G15ARac1 mutant, but the level of binding was not increased by VEGF 
treatment. Control experiments using GST showed no evidence of non-specific GEF 
binding. We have also observed that silencing of VEGFR-2 by RNAi perturbs VEGF-
stimulated Vav2 binding to G15ARac1 (Fig. 2.5B).  These results indicated that of the 
GEFs examined only Vav2 increased its association with G15ARac1 after VEGF 
stimulation through the VEGFR-2 signaling.  
To study further the role of Vav2 in VEGF-induced Rac1 activation, we used two 
different siRNA against Vav2 to decrease Vav2 expression in endothelial cells.  Silencing 
Vav2 resulted in a decrease of Vav2 protein expression, but no changes in Vav3, Sos1 or 
β-actin (Fig. 2.6A).  Following knockdown of Vav2 expression there was impaired Rac1 
activation in response to VEGF in both HUVECs and HMVEC-d.  In the HUVECs, we 
used two different siRNA oligos against Vav2 and observed comparable results (Fig. 
2.6B).    Silencing Vav2 with siRNA did not affect expression of Vav3 in HMVEC-d 
(data not shown). Collectively, these experiments suggest that Vav2 expression is 
required for VEGF-induced Rac1 activation at the 30 min time point in these two 
endothelial cell types.  
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Figure 2.4  Rac GEF mRNA and protein expression. 
(A) mRNA transcripts of Vav proteins in endothelial cells.  Equivalent amounts of 
HUVEC, HMVEC-d, and Jurkat T cells mRNA was analyzed by RT-PCR for Vav 
proteins.  β-actin was used as a loading control. (B) Endogenous protein expression of 
candidate Rac1 GEFs in endothelial cells.  Equivalent total protein from HMVEC-d, 
HUVECs or COS7 cells was probed with antibodies against the specific Rac1 GEFs 
Vav2 and Vav3. Similarly, expression of Vav1 was probed in HMVEC-d, HUVECs, or 
Jurkat T cells. Equivalent levels of protein from HUVECs or COS7 cells were also 
probed with antibodies against other Rac1 GEFs, Sos1 and β-PIX.  β-actin (bottompanel) 
indicated equal amount of protein was loaded. 
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Figure 2.5  VEGF stimulates Vav2-Rac1 complex formation.  
(A) Pharmacological inhibitor of VEGFR-2 perturbs Vav2-Rac1 complex formation. 
HUVECs were serum-starved and then pretreated in the presence or absence of 50 μM 
SU1498.  Cells were treated with 10 ng/mL VEGF for 30 min, lysed, and lysates were 
incubated with the nucleotide-free Rac1 mutant fused to GST (GST-G15ARac1) on 
glutathione-Sepharose beads for 60 min at 4°C.  Antibodies against Vav2 (upper panel), 
Sos1 (middle panel), and β-Pix (lower panel) were used to detect binding of these 
proteins to G15ARac1. The histogram shows the % GEF association to G15ARac1 in 
four independent experiments (n = 4; *p < 0.05). (B) Knockdown of VEGFR-2 by RNAi 
attenuates Vav2-Rac1 complex formation. HUVECs were transfected with either non-
specific control or siRNA oligos against VEGFR-2. After 24 h, cells were serum-starved 
and then pretreated in the presence or absence of 10 ng/mL VEGF for 30 min.  Cells were 
lysed and the protein concentration was normalized. Lysates were then incubated with the 
nucleotide-free Rac1 mutant fused to GST (GST-G15ARac1) on glutathione-Sepharose 
beads for 60 min at 4°C.  Polyclonal antibody against Vav2 (upper right panel) was used 
to detect binding to G15ARac1. Efficient knockdown of VEGFR-2 protein levels was 
also detected (lower right panel).   
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Figure 2.6  Silencing of Vav2 by siRNA inhibits VEGF-induced Rac1 activation. 
(A) Knockdown of Vav2 protein expression with Vav2-specific siRNA.   HUVECs were 
transfected with either non-specific control siRNA (siGLO) or two different Vav2-
specific siRNA oligos as described in Materials and Methods. The upper left panel shows 
that Vav2 expression was significantly decreased by both siRNAs. Expression of Vav3 
(middle left panel), Sos1 (middle left panel) and β-actin (lower left panel) were 
unaffected by Vav2 siRNA. The histogram on the right illustrates the fold change in 
Vav2 protein expression after siRNA, but no change in Sos1 expression (n = 3; **p < 
0.01). (B) Depleting Vav2 by siRNA perturbs Rac1 activation.  HUVECs (top panels) or 
HMVEC-d (bottom panels) were transfected with Vav2-specific siRNA.  After 24 h, the 
cells were serum-starved for 1 h, treated with VEGF for 30 min and assayed for active 
Rac1.  The upper left panel shows that Vav2 siRNA cells prevented VEGF-induced Rac1 
activity compared to control cells. The middle left panel shows equal levels of total Rac1.  
The lower left panel shows knockdown of Vav2 expression by siRNA. The histogram on 
the right shows the average Rac1 activation relative to total Rac1 levels in three 
independent experiments (n = 3; *p < 0.05 by 2-way ANOVA).   
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Vav2 is tyrosine phosphorylated in response to VEGF – The pulldown assay with 
G15ARac1 suggested that Vav2 is activated downstream of VEGF treatment. Given that 
Vav2 is tyrosine phosphorylated in response to EGF and PDGF signaling, and that 
tyrosine phosphorylation has been associated with Vav2 activation 213,228, we examined 
the tyrosine phosphorylation of Vav2 following VEGF treatment. We found that Vav2 
tyrosine phosphorylation was stimulated by VEGF and peaked at 30 min of VEGF 
stimulation.  VEGF did not induce detectable tyrosine phosphorylation of Sos1 (Fig. 2.7).    
To determine whether tyrosine phosphorylation of Vav2 was downstream of VEGFR-2, 
we applied the pharmacological inhibitors of VEGFR-2 used earlier to inhibit Rac1 
activation. Both SU1498 and ZM323881 prevented Vav2 tyrosine phosphorylation in 
response to VEGF (Fig. 2.8A). In addition, silencing VEGFR-2 with siRNA decreased 
VEGF-induced Vav2 tyrosine phosphorylation (Fig. 2.8B). These results suggest that 
VEGF-induced Vav2 tyrosine phosphorylation requires VEGFR-2 signaling.    
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Figure 2.7  Vav2, but not Sos1, is tyrosine phosphorylated after VEGF stimulation. 
Serum-starved HUVECs were stimulated with 10 ng/mL VEGF, endogenous Vav2 or 
Sos1 immunoprecipitated, and then probed for phosphotyrosine. Vav2 is tyrosine 
phosphorylated after VEGF stimulation and peaked at 30 min (upper panel, first image). 
However, Sos1 was not tyrosine phosphorylated by VEGF treatment up to 30 min (upper 
panel, second image). The middle panels show equal protein levels in every 
immunoprecipitation, whereas the lower panel shows equal protein loading in cell 
lysates.  
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Figure 2.8  Suppressing VEGFR-2 signaling or expression inhibits Vav2 tyrosine 
phosphorylation. 
(A)  Vav2 tyrosine phosphorylation is blocked with VEGFR-2 inhibitors.  Cells were 
pretreated with 50 μM SU1498 or 10 nM ZM323881 for 30 min at 37°C, followed by 
VEGF addition for 30 min.  In the upper panel, immunoprecipitates of Vav2 were probed 
with anti-phosphotyrosine antibody, showing that inhibiting VEGFR-2 signaling prevents 
Vav2 tyrosine phosphorylation.  The middle panel shows equal Vav2 levels in every 
immunoprecipitation, and the lower panel shows equal protein loading in cell lysates. 
Blots are representative of at least three independent experiments. (B)  Vav2 tyrosine 
phosphorylation is blocked with VEGFR-2 siRNA.  HUVECs were transfected with 
either non-specific control siRNA (siGLO) or VEGFR-2-specific siRNA oligos as 
described in Materials and Methods .Cells were assayed 24 h after transfection with 
VEGFR-2-specific siRNA.  Serum-starved cells were stimulated with 10 ng/mL VEGF, 
endogenous Vav2 immunoprecipitated, and then probed for phosphotyrosine. The upper 
left panel shows that VEGFR-2 siRNA cells prevented Vav2 tyrosine phosphorylation 
after 30 min VEGF stimulation compared with control cells. The middle panels confirm 
equal Vav2 levels in every immunoprecipitation and equal protein loading in cell lysates. 
The lower panel shows levels of VEGFR-2 expression after siRNA treatment.  The 
histogram on the right shows the average Vav2 tyrosine phosphorylation relative to total 
Vav2 levels in four independent experiments (n = 4; *p < 0.05 by 2-way ANOVA).   
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Tyrosine phosphorylation of Vav2 is mediated by Src – The non-receptor tyrosine kinase 
Src is a known effector of VEGF signaling and is important for endothelial cell migration 
28,250,251. Previous work has demonstrated that Src phosphorylates exchange factors that 
activate Rho proteins 214,252,253.  To confirm that Src is activated by VEGF, we used 
phosphospecific antibodies that bind to phosphorylated tyrosine 418 of Src.  This tyrosine 
residue is found in the activation loop of Src and its phosphorylation leads to Src 
activation 254.  VEGF treatment of HUVECs stimulated Src phosphorylation at tyrosine 
418 and this was blocked by the Src inhibitor PP2 (Fig. 2.9A). To investigate the role of 
Src in Vav2 tyrosine phosphorylation, Src kinase activity was blocked with PP2.  
Immunoprecipitations with Vav2 revealed that, in response to VEGF, Vav2 tyrosine 
phosphorylation was decreased in cells treated with PP2, whereas the inactive analog PP3 
did not affect Vav2 tyrosine phosphorylation (Fig. 2.9B).  It has been shown previously 
that phosphorylation of tyrosine 172 in Vav2 relieves an intramolecular inhibition, 
potentially resulting in increased activity of Vav2 by allowing access to the DH domain 
225,228. Using a phosphospecific antibody, we explored whether Vav2 was specifically 
phosphorylated at tyrosine 172 upon VEGF treatment. VEGF treatment induced 
phosphorylation of Vav2 on tyrosine 172 (Fig. 2.9C). This phosphorylation was blocked 
by PP2, but not PP3, suggesting that this phosphorylation depended on Src kinase 
activity. Lastly, to determine if Src kinase activity in turn perturbs Rac1 activation, we 
treated cells with the Src inhibitors PP2 or SU6656. Both inhibitors, but not PP3, 
abolished VEGF-induced Rac1 activation (Fig. 2.10). These results were also seen in 
HMVEC-d (data not shown).  Together, these data indicate that VEGF-induced tyrosine 
phosphorylation of Vav2, in particular on tyrosine 172, is regulated by Src and that Src 
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kinase activity is required for activation of Rac1 in response to VEGF.  
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Figure 2.9  Inhibition of Src blocks Vav2 tyrosine phosphorylation. 
(A) Serum-starved HUVECs were pretreated with either 30 μM PP2 (Src inhibitor) or 
PP3 (the inactive analog) for 30 min at 37°C and then treated with VEGF.  Untreated (un) 
denotes cells not treated with 10 ng/mL VEGF for 30 min.  Lysates were immunoblotted 
for phosphorylation of tyrosine 418 on Src and showed that Src is catalytically activated 
after VEGF treatment (upper panel). PP2, but not the control compound PP3, blocks Src 
tyrosine phosphorylation. The middle panel shows equal Src levels in every 
immunoprecipitation, whereas the lower panel shows equal protein loading in cell 
lysates. The histogram on the right shows the average Src tyrosine phosphorylation 
relative to total Src levels in three independent experiments (n = 3; *p < 0.05). (B) Src 
inhibition blocks Vav2 tyrosine phosphorylation. HUVECs were serum starved, 
pretreated either 30 μM PP2 (Src inhibitor) or PP3 (the inactive analog) for 30 min at 
37°C and then treated with VEGF .  Cells were lysed and Vav2 was immunoprecipitated 
followed by immunoblotting for phosphotyrosine. Inhibiting Src with PP2 prevents Vav2 
tyrosine phosphorylation, whereas Vav2 phosphorylation was unaffected by PP3 (upper 
panel). The middle panel shows equal Vav2 levels in every immunoprecipitation, 
whereas the lower panel shows equal protein loading in cell lysates. The histogram on the 
right shows the average Vav2 tyrosine phosphorylation relative to immunoprecipitated 
Vav2 levels in three independent experiments (n = 3; *p < 0.05). (C) The Src inhibitor 
PP2 blocks Vav2 phosphorylation specifically on tyrosine 172. Serum-starved HUVECs 
were pretreated either 30 μM PP2 (Src inhibitor) or PP3 (the inactive analog) for 30 min 
at 37°C and then treated with VEGF.  Phosphorylation of Vav2 on Y172 was analyzed by 
western blotting using a phospho-epitope-specific antibody. The upper panel shows that 
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inhibition of Src with PP2 prevents phosphorylation at this residue. The middle panel 
shows equal Vav2 levels in every immunoprecipitation, whereas the lower panel shows 
equal protein loading in cell lysates.  The histogram on the right shows the average Vav2 
phosphorylation on tyrosine 172 activation relative to total Vav2 expression in four 
independent experiments (n = 4; *p < 0.05). 
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Figure 2.10  VEGF-induced Rac1 activation is regulated by Src activity.  
HUVECs were serum starved for 1 h, pretreated with either 30 μM PP2 or 5 μM SU6656 
(Src inhibitor) or 30 μM PP3 for 30 min at 37°C. Cells were then treated with 10 ng/mL 
VEGF and subsequently assayed for Rac1 activity as described in Materials and 
Methods. The upper left panel shows Rac-GTP levels after VEGF treatment. The lower 
left panel shows total Rac1 levels. The histogram on the right shows quantification of the 
increase in Rac1 activity after VEGF stimulation. Data is representative of five 
independent experiments (n = 5; *p < 0.05, **p < 0.01).   
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Vav2 is necessary for VEGF-induced endothelial cell migration – Previous work has 
shown that VEGF stimulates HUVEC migration 23,25,143. Since our findings suggested 
that Vav2 specifically activates Rac1 during VEGF signaling, we investigated whether 
Vav2 was required for the migration of HUVECs and HMVEC-d towards VEGF.   We 
knocked down expression of Vav2 in both cell types using siRNA and assayed for 
chemotactic migration across Transwell filters. As expected, we found that migration of 
endothelial cells was increased when a VEGF gradient was present (Fig. 2.11, closed 
bars). However, migration was significantly decreased in both endothelial cell types 
when Vav2 was depleted using siRNA. Studies performed in HUVECs with two different 
siRNAs against Vav2 showed similar results (Fig. 2.11). Since Vav2 is known to activate 
not only Rac1 but also RhoA and Cdc42 in vitro, we determined if silencing of Rac1 
conferred similar migratory defects as seen with Vav2 siRNA. Using siRNA against 
Rac1 to knockdown Rac1 expression, we found that HUVEC migration towards VEGF 
was significantly decreased as was seen with the knockdown of Vav2 (Fig. 2.12).  These 
observations show that Vav2 expression contributes to chemotactic migration of 
endothelial cells towards VEGF and that Rac1 is important for this migration.  To 
investigate further the role of Vav2 in HUVEC migration, we performed a “scratch 
wound” assay comparing migration of HUVECs in which Vav2 levels had been 
depressed by siRNA with cells expressing control siRNA.  After being stimulated with 
VEGF, endothelial cells depleted of Vav2 by siRNA revealed decreased wound closure 
compared to control cells (Fig. 2.13).  
 
 
  96
 
 
 
 
 
 
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
Vav2 siRNANon-specific 
siRNA
- VEGF
+ VEGF
Fo
ld
 C
he
m
ot
ax
is
 
(in
 H
M
VE
C
-d
)
ND **
α-Vav2
α-β-actin
No
n-s
pe
cif
ic 
siR
NA V
av
2 
siR
NA
HMVEC-d:
Fo
ld
 C
he
m
ot
ax
is
 
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
Vav2        
siRNA #1  
Non-specific 
siRNA
Vav2        
siRNA #2  
**
*5.5
6
6.5 ND
ND
- VEGF
+ VEGF
No
n-
sp
ec
ifi
c 
siR
NA
α-β-actin
α-Vav2
Va
v2
 
siR
NA
 #1
HUVECs:
Va
v2
 
siR
NA
 #2
α-Vav3
Fo
ld
 C
he
m
ot
ax
is
 
(in
 H
M
VE
C
-d
)
Fo
ld
 C
he
m
ot
ax
is
 
(in
 H
M
VE
C
-d
)
Fo
ld
 C
he
m
ot
ax
is
 
Fo
ld
 C
he
m
ot
ax
is
 
  97
Figure 2.11  Vav2 silencing by siRNA reduces endothelial cell chemotaxis.  
HUVECs (top panels) or HMVEC-d (bottom panels) were transfected with either non-
specific control (siGLO) or Vav2-specific siRNA. For the HUVECs, two different Vav2 
siRNA was used, whereas for HMVEC-d one Vav2 siRNA oligo was used.  Blots 
indicate efficient knockdown of Vav2 protein levels, but not Vav3 protein levels.  Cells 
were allowed to migrate for 4 h towards non-specific control media (open bars) or media 
containing 10 ng/ mL VEGF (closed bars) using Transwell filters.  Chemotaxis was 
quantified by calculating the mean number of cells that had migrated on the underside of 
the Transwell filter in three separate fields per filter ± standard deviation of triplicate 
independent experiments (n = 3; ** p < 0.01; *p < 0.05; ND, not significantly different 
by 2-way ANOVA).   
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Figure 2.12  Silencing of Rac1 decreases HUVEC migration towards VEGF.  
HUVECs were transfected with either non-specific control (siGLO) or Rac1-specific 
siRNA. Blots indicate efficient knockdown of Rac1 protein levels.  Cells were allowed to 
migrate for 4 h towards non-specific control media (open bars) or media containing 10 
ng/ mL VEGF (closed bars) using Transwell filters.  Chemotaxis was quantified by 
calculating the mean number of cells that had migrated on the underside of the Transwell 
filter in three separate fields per filter ± standard deviation of triplicate independent 
experiments (n = 3; ** p < 0.01; ND, not significantly different by 2-way ANOVA).   
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Figure 2.13  Knockdown of Vav2 by siRNA prevents VEGF-induced wound closure.  
Cells transfected with either control siRNA or Vav2-targeting siRNA were wounded with 
a pipette tip and allowed to invade the wound for 48 h in the presence of 10 ng/mL 
VEGF.  Wound closure was visualized by phase microscopy. The distance of wound 
closure is the average wound closure on three distinct points on each image over time and 
divided by the average initial wound size.  At least five images were collected at each 
time point. Bar, 100 μm. The graph shows the mean distance of wound closure in three 
independent experiments (n = 3; *p < 0.05; ** p < 0.01). 
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DISCUSSION 
 
VEGF signaling is well-characterized in the context of endothelial cell behavior 
and function, but relatively little is known about the downstream proteins that directly 
facilitate biological responses.  Our finding that VEGF causes both early (1-5 min) and 
late (30 min) activation of Rac1 demonstrates that VEGF signaling controls Rac1 activity 
in a time-dependent manner. This finding is similar to recent data shown by Aoki et al. 
255 in PC12 cells stimulated with nerve growth factor (NGF), suggesting that biphasic 
Rac1 activation occurs in different cell types in response to cell-specific stimuli.   Our 
work has focused on the late phase of Rac1 activation in response to VEGF stimulation 
since Rac1 activation was most pronounced at these later stages. 
Currently, it is unclear how specific exchange factors couple growth factor 
signaling to Rho proteins, thereby allowing these proteins to coordinate finely-
orchestrated biological responses. Though several studies showed that VEGF causes 
endothelial cell migration by inducing Rac1-stimulated lamellipodia formation, the 
pathway between VEGF signaling and Rac1 activation was not explored 23.  In this study, 
we identified the exchange factor Vav2 as mediating VEGF signaling to Rac1.  Using a 
nucleotide-free G15ARac1 mutant, we showed that Vav2 interacts with Rac1 after VEGF 
stimulation and this association correlated with a robust increase in Rac1 activity. 
Additionally, we observed that VEGF stimulated tyrosine phosphorylation of Vav2. This 
tyrosine phosphorylation was prevented by inhibiting either VEGFR-2 signaling or Src 
kinase activity. Moreover, knockdown of Vav2 not only inhibited the increase in Rac1 
activity in response to VEGF stimulation, but also inhibited VEGF-stimulated migration.  
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Together these results indicate that Vav2 plays a critical role in the response to VEGF.  It 
is interesting that the related GEF, Vav3, was also detected at low levels in HMVEC-d.  
The similarity of this GEF to Vav2 raises the possibility that it too may contribute to 
Rac1 activation downstream from VEGF stimulation. However, because the knockdown 
of Vav2 significantly decreases VEGF-induced Rac1 activation and cell migration, the 
contribution of Vav3 to this response must be small at best. 
Vav2 is one of the better characterized Rac1 GEFs and in several cell types is 
necessary for processes that require rearrangement of the actin cytoskeleton, including 
spreading and migration 193,196,214. Recent data have shown that Vav2 is critical for Rac1 
activity downstream of both adhesion molecules and growth factor receptors in diverse 
cell types.  Two recent studies have shown that Vav2 is involved in nectin- and E-
cadherin-induced activation of Rac1 in MDCK cells 208,209.  Similarly, Vav2 has been 
implicated in neuronal cell migration and neurite outgrowth mediated by adhesion 
molecule L1 219, and Rac1-dependent Schwann cell migration 256.  Vav2 has also been 
shown to promote cell migration in response to EGF and UTP nucleotide signaling 
211,213,257.  We conclude that Vav2 is an exchange factor commonly used by cells to 
activate Rac1 and promote migration in response to diverse signaling pathways. 
In immunoprecipitation studies, we observed that Vav2 may not directly associate 
with VEGFR-2 (Fig. 2.17), thus other intermediate proteins may link VEGF signaling to 
Vav2 activity. Vav2 is regulated by tyrosine phosphorylation and/or membrane targeting, 
but the exact regulatory mechanism is controversial. Vav2 is tyrosine phosphorylated in 
response to EGF and PDGF signaling and this phosphorylation correlates with enhanced 
migration of fibroblasts 213,228,258. However, it is still unclear whether this tyrosine 
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phosphorylation directly regulates Vav2 exchange activity.   
Work from other labs has indicated that the non-receptor tyrosine kinase Src may 
phosphorylate Vav2 downstream of VEGF signaling 253,259. Eliceiri et al. 259 showed that 
endogenous Src kinase activity is required for VEGF-induced angiogenesis.  Another 
study showed that Vav2 is tyrosine phosphorylated in cells transfected with an active 
form of c-Src (Src Y529F) 253. Overexpression of wild-type Vav2 fails to activate Rac1 
or induce lamellipodia formation in cells that are expressing a dominant negative Src or 
cells that are treated with Src inhibitor PP2 214 .  These data support a role for Src in Vav2 
activation. Gavard and Gutkind 115 published that Src-dependent phosphorylation of 
Vav2 upon VEGF stimulation promotes VE-cadherin endocytosis, contributing to 
endothelial cell permeability. To complement those studies, we show here that VEGF-
induced Vav2 tyrosine phosphorylation and downstream activation of Rac1 depends on 
Src kinase activity in endothelial cells and is responsible for migration and wound 
closure. Collectively, these data illustrate an important role for Vav2 in endothelial cells 
responding to VEGF.  Work by Sauzeau et al. 206 has shown that Vav2 knockout mice 
have defects in cardiovascular function characterized by an increase in hypertension and 
tachycardia, suggesting that Vav2 is not only essential for the regulation of endothelial 
cells, but other vascular cells as well. Our hypothesized model is illustrated in Fig. 2.14. 
The stimulation of endothelial migration by VEGF is important for normal 
angiogenesis. However, there are several situations where angiogenesis can have 
pathological consequences. For example, much attention has been paid to the 
vascularization of tumors, which facilitates tumor growth.  Similarly, inappropriate blood 
vessel formation underlies several pathological situations, such as age-related macular 
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degeneration.  Understanding the signaling pathways by which VEGF stimulates Rac1 
activation and cell migration may reveal new therapeutics targets.  Our identification of 
Vav2 as an exchange factor activated in response to VEGF stimulation suggests Vav2 as 
a potential target for drug development.  
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Figure 2.14  Proposed model of VEGF signaling to Rac1 through Rac GEF Vav2 in 
endothelial cell migration.  
This model proposes the hypothetical signaling pathway coupling VEGF signaling to 
small GTPase Rac1 activation during endothelial cell migration through Rac GEF Vav2 
in a VEGFR-2- and Src-dependent manner. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
CHAPTER THREE 
VEGF SIGNALS THROUGH REACTIVE OXYGEN SPECIES (ROS) TO 
REGULATE ADHERENS JUNCTIONS  
 
ABSTRACT 
 
Vascular permeability describes the capacity of endothelial cells to form 
intercellular pores allowing for the passage of small molecules and immune cells to 
underlying tissues. Aberrant vascular permeability has been observed in several 
inflammatory disorders such as rheumatoid arthritis, psoriasis, and atherosclerosis.  
Vascular endothelial growth factor (VEGF) is a well-known mediator of endothelial cell 
proliferation, migration, and tube formation, but it was first shown to stimulate 
permeability in vivo.  VEGF upregulates the production of reactive oxygen species 
(ROS), signaling molecules that have recently been shown to regulate the 
phosphorylation state of specific adherens junction proteins in a Rac1-dependent manner.  
Phosphorylation of these proteins weakens their interaction with adjacent cells, which 
weakens cell-cell junctions.  However, it is unknown if VEGF acts through ROS to cause 
phosphorylation of adherens junction proteins and promote vascular permeability.  The 
goal of this study was to investigate whether VEGF-induced ROS production promotes 
phosphorylation of adherens junction proteins to decrease endothelial barrier integrity.  
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We show that VEGF increases ROS production in endothelial cells using p38 MAPK 
phosphorylation as a downstream readout; further, inhibiting ROS production with N-
acetylcysteine (N-Ac) prevents p38 MAPK phosphorylation after VEGF stimulation.  We 
also show that adherens junction proteins VE-cadherin and β-catenin are tyrosine 
phosphorylation in response to VEGF and N-Ac pretreatment can inhibit 
phosphorylation.  Additionally, VE-cadherin is phosphorylated on two critical tyrosine 
residues (Tyr685 and Tyr731), which when not phosphorylated, respectively bind β-
catenin and p120catenin to associate with the actin cytoskeleton.  Together, our results 
offer preliminary evidence that VEGF signals through ROS to regulate adherens junction 
proteins in endothelial cells, thereby modulating vascular permeability. 
 
INTRODUCTION 
 
 The internal lining of blood vessels is composed of an endothelial cell monolayer 
(endothelium) that forms a barrier to keep fluid in the lumen, but also regulates transport 
soluble factors and immune cells to infected and injured tissues in a process known as 
vascular permeability.  During vascular permeability, disrupted cell-cell junctions create 
gaps between adjacent cells to allow movement across the endothelium.  Dysregulated 
permeability causes swelling in surrounding tissues due to excessive leakage of blood or 
lymph fluid (edema) and abnormal inflammation due to inappropriate transendothelial 
migration (TEM) of leukocytes.  Edema and TEM can occur in response to vascular 
endothelial growth factor (VEGF) secreted from hypoxic or activated cells, confirming its 
initial description as a potent permeability factor9,28,260,261.  VEGF increases permeability 
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of several types of endothelial cell types in vitro, particularly human umbilical vein 
endothelial cells (HUVECs) that form fenestrations in response to VEGF33,262.  The 
mechanisms responsible for VEGF-induced permeability are not fully defined.   
One mechanism possibly used by VEGF to mediate permeability is acting on 
proteins at intercellular junctions of endothelial cells such as adherens junctions.  
Adherens junctions form contacts with adjacent cells through the regulation of a multi-
protein complex, namely vascular endothelial (VE)-cadherin, β-catenin, α-catenin, 
plakoglobin/γ-catenin, and p120catenin. Collectively, these proteins form and stabilize 
cell-cell adhesions to form a protective barrier that tightly regulates paracellular 
movement. Within this complex, barrier integrity is largely dependent on VE-cadherin, a 
transmembrane glycoprotein that mediates homophilic, and sometimes heterophilic, 
interactions through its extracellular cadherin domains in a calcium-dependent manner.  
Intracellularly, VE-cadherin binds β-catenin via its cytoplasmic tail, which then 
associates with α-catenin to link the complex to the actin cytoskeleton.  In addition to 
binding VE-cadherin, plakoglobin can also target to desmosomes, another cell-cell 
adhesion complex263. The ability of plakoglobin to dually target VE-cadherin to adherens 
junctions or desmosomes displays its unique role in the coordination of these distinct 
adhesive complexes. Moreover, VE-cadherin binds p120catenin at its juxtamembrane 
region, which stabilizes VE-cadherin on the plasma membrane, thereby negatively 
regulating its endocytosis and inhibiting permeability109,264. VEGF can modulate 
adherens junctions by regulating phosphorylation of these proteins on crucial tyrosine 
residues.  Work from several groups have shown that tyrosine phosphorylation of 
adherens junction proteins promotes junctional disassembly and cell 
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migration29,122,259,265,266.  This disassembly may occur either from the internalization of 
adhesion proteins or detachment from the actin cytoskeleton. Specifically, VEGF 
regulates tyrosine phosphorylation of  VE-cadherin, β-catenin, plakoglobing/γ-catenin, 
and p120catenin, but not α-catenin, suggesting that VEGF may regulate vascular 
permeability through one or more of these proteins115,122,266,267.  A model of proteins 
involved in VEGF-regulated vascular permeability is illustrated in Figure 3.1. 
The Rho family of small GTPases has been identified as regulators of cell-cell 
adhesion through cadherin-catenin complex. Rac, a member of this family, mediates the 
formation and activity of cell-cell junctions in epithelial and endothelial cells.  In both 
cell types, Rac is necessary for the assembly of adherens and tight junctions and the 
disassembly of these junctions in response to permeability agonists such as 
VEGF24,169,268,269.  Rac promotes junctional disassembly by aiding in the production of 
reactive oxygen species (ROS) that are derived from the NADPH oxidase in endothelial 
cells29. ROS are free radicals or free radical products that inactivate protein tyrosine 
phosphatases (PTPs), which then regulate the phosphorylation state of proteins at cell-cell 
junctions, particularly adherens junctions27. Moreover, ROS can lead to endothelial 
barrier dysregulation with subsequent increased vascular permeability29,270. The most-
generated ROS in endothelial cells are superoxide (O2-) and hydrogen peroxide (H2O2).  
It has been shown that exogenous H2O2 can increase VEGF expression in vitro and in 
vivo; conversely, VEGF stimulation increases endogenous H2O2 production271,272. 
However, as pertains to cell-cell junctions, whether VEGF-induced ROS production 
induces tyrosine phosphorylation of adherens junction proteins remains elusive.  In this 
study, we asked whether VEGF acts through ROS to induce tyrosine phosphorylation of 
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adherens junction proteins, and if phosphorylation leads to junctional disassembly.  The 
results have revealed that VEGF promotes tyrosine phosphorylation of adherens junction 
proteins VE-cadherin and β-catenin in a ROS-regulated manner, and ROS may affect 
binding of β-catenin to VE-cadherin to induce vascular permeability.  
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Figure 3.1  Model of proteins involved in vascular permeability. 
 
This model describes the proteins and signaling pathways involved in vascular 
permeability.    Shear stress or circulating cells induce the release of soluble VEGF to 
confer signals to vascular endothelium facing the blood vessel lumen.  VEGF signaling 
via VEGFR-2 can act through several different pathways to disrupt cell-cell junctions, 
namely tight junctions, adherens junctions, and gap junctions.  ROS, PTPs, and Src 
family tyrosine kinases can regulate phosphorylation of junctional components to cause 
disassembly.  VEGF signaling on the basolateral side of the endothelial cell can also 
affect permeability.  VEGF released from smooth muscle cells, or pericytes, stromal 
cells, and tumor cells can activate VEGFR-2. In addition, the receptor is activated by 
VEGF bound to proteins comprising the ECM and basement membrane. αv integrin 
interacts with VEGFR-2 to synergize signals from cell-matrix adhesion.  These signals 
can facilitate permeability by promoting cytoskeletal contraction through PAK or 
upregulate gene transcription through Src and FAK. (Model adapted from Weis and 
Cheresh, Nature Rev, 2004) 
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MATERIALS AND METHODS 
 
Cell culture - Pooled human umbilical vein endothelial cells (HUVECs) were obtained 
from Cambrex (East Rutherford, NJ) and grown in Clonetics EGM-2 media according to 
manufacturer’s instructions at 37°C and 10% CO2.  Cells were used between passages 3-
6.   
Antibodies and pharmacological reagents - Anti-phosphotyrosine (pY99) mAb and VE-
cadherin pAb were obtained from Santa Cruz Biotechnology (Santa Cruz, CA).  β-
catenin pAb was obtained from Sigma (St. Louis, MO).  Phospho-p38 MAPK and total 
p38 MAPK pAbs were purchased from Cell Signaling Technology (Beverly, MA). 
Phospho-VE-cadherin (pY658) and (pY731) rabbit-pAb was purchased from Biosource 
(Camarillo, CA). Recombinant human VEGF165 was purchased from R&D Systems 
(Minneapolis, MN).  N-acetylcysteine (N-Ac) was purchased from Calbiochem (San 
Diego, CA).  Glutathione-Sepharose was purchased from Amersham Biosciences 
(Uppsala, Sweden).  
GTPase activation assays - The GTPase activity of Rac1 was measured as previously 
described 242 with some modifications. Cells were rinsed with cold PBS and lysed in 
RIPA buffer as described. Lysates were cleared by centrifugation and protein 
concentration was measured. Equal amounts of protein (400-600 μg) were incubated with 
50 μg GST fusion protein of the CRIB-binding domain of PAK (GST-PBD) bound to 
glutathione-Sepharose beads for 30 min at 4°C.   Beads were washed three times in 
buffer (50 mM Tris-HCl, pH 7.6, 500 mM NaCl, 1% Triton X-100, 0.5 mM MgCl2, 1 
mM  PMSF,   10 μg/mL  leupeptin,  10 μg/mL aprotinin) and associated proteins were 
eluted with sample buffer.  The amount of active Rac1 was then analyzed by 
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immunoblotting and quantified by densitometric analysis using ImageJ software (NIH). 
Immunoprecipitation and immunoblotting - For immunoprecipitation, HUVECs were 
then pretreated with 5mM N-acetylcysteine for 14 h at 37°C.  Cells were starved in 
serum-free Optimem media for 1 h at 37°C under 10% CO2. Subsequently, cells were 
treated with 10 ng/mL VEGF165 for the time specified. Cells were rinsed with PBS with 1 
mM CaCl2 and 1 mM MgCl2 prior to scraping into modified hot SDS lysis buffer (10 mM 
Tris-HCl, pH 7.6, 2 mM EDTA, 2% SDS, 0.5 mM DTT) on ice.  Lysates were boiled for 
10 min, clarified by centrifugation at 16,000 x g for 10 min, diluted with stringent buffer 
containing TBS, 1% Triton-X 100, 1% DOC, 10 mM pervanadate, and then incubated 
with antibody and beads for 4 h at 4°C.  The beads were washed three times in wash 
buffer (TBS, 1% Triton-X 100, 1% DOC, 10 mM pervanadate) and bound proteins were 
eluted with SDS sample buffer. 
For immunoblotting, cells were washed in cold HBS and scraped into hot SDS 
lysis buffer (10 mM Tris-HCl, pH 7.6, 2 mM EDTA, 2% SDS, 0.5mM DTT).  Cells were 
lysed on ice, boiled and clarified by centrifugation.  For both techniques, protein 
concentrations were determined using a detergent-compatible (DC) protein assay kit 
(Bio-Rad, Hercules, CA) according to the manufacturer’s instructions.  Equal amounts of 
total protein were denatured in SDS sample buffer, run on 10% SDS-polyacrylamide gels 
and transferred to Immobilon-P membrane. Blots were probed with primary antibody and 
then horseradish peroxidase-conjugated secondary antibody, visualized by enhanced 
chemiluminescence according to the manufacturer’s instructions. 
Statistical Analysis - Statistical analysis was calculated using Student’s t-test.   
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RESULTS 
VEGF activates Rac1 and p38 in ROS pathway  –  In Chapter 2, the data showed 
Rac1 activity was transiently increased up to 5 min following VEGF stimulation.  This 
data confirmed work by Zeng et al. (2002) showing a rapid and transient increase in Rac1 
activity around 5 min of VEGF treatment26.  Here we show that 1 min activation of Rac1 
after VEGF treatment in HUVECs using GST-PBD to pulldown Rac-GTP as shown in 
Fig. 3.2.  This early time point may temporally correlate with vascular permeability that 
occurs in response to VEGF.   
ROS such as H2O2 is produced downstream of Rac1 activation in HUVECs.  
H2O2 has been shown to reduce cadherin-based adherens junction contacts between 
adjacent cells.  van Wetering and coworkers showed that a cell-permeable, constitutively 
active Rac1 forms paracellular pores in HUVEC monolayers in a ROS-dependent 
manner29.  The same group showed that loss of VE-cadherin-mediated adhesions requires 
Rac1 activation and ROS production30. Further, VEGF signaling can increase 
endogenous concentrations of ROS in endothelial cells272. Phosphorylation of p38 MAPK 
is often used as a readout of endogenous ROS production. MAP kinases are important 
signaling molecules that promote cell growth, proliferation, and responses to external 
stimuli, especially stimuli that cause oxidative stress.  In particular, p38 MAPK is 
characterized as the stress activated protein kinase (SAPK) because it is phosphorylated 
downstream of cellular stress.  In our preliminary work, we found that VEGF stimulates 
phosphorylation of p38 as early as 2 min that extends to 15 min (Fig. 3.3).  Quantification 
of these data displayed an approximate 1.5-fold increase in phosphorylation after VEGF 
stimulation compared to control, non-treated cells.  These data confirm seminal work 
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from Jacques Hout’s laboratory that showed VEGF stimulated p38 MAPK and 
JNK/SAPK1 phosphorylation in HUVECs, which subsequently promoted cell migration 
and stress fiber formation143,273.  Overall, these results suggest that VEGF acts at many 
levels of the pathway resulting in ROS production. 
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Figure 3.2 Rac1 is activated after 1 min VEGF treatment. 
HUVECs (top panels) or HMVEC-d (bottom panels) were serum starved for 1 h and 
treated with 10 ng/mL VEGF for 1 min and subsequently assayed for Rac1 activity as 
described in Materials and Methods. The upper left panel shows Rac-GTP levels after 
VEGF treatment. The lower left panel shows total Rac1 levels. Blots are representative of 
four independent experiments. 
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Figure 3.3 Treatment of endothelial cells with VEGF induces p38 phosphorylation. 
HUVECs were serum starved for 1 h and treated with 10 ng/mL VEGF for the specified 
times and immunoblotted for phospho-p38. The upper panel shows phosphorylated p38 
after VEGF treatment. The lower left panel shows total levels of p38 expression. The 
histogram on the right shows quantification of the fold increase in phosphorylated p38 
after VEGF stimulation in four independent experiments (n=4). 
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ROS scavenger N-acetylcysteine inhibits p38 MAPK, VE-cadherin and β-catenin 
phosphorylation - In immune cells, Rac activity is necessary for ROS generation due to 
its activation of the NADPH oxidase complex274. A similar mechanism has been 
identified in endothelial cells, where the NAPDH oxidase complex is the major producer 
of ROS in this cell type171.  Moreover, exogenous treatment of endothelial cells with 
H2O2 markedly decreases cell-cell adhesion275.  N-acetylcysteine (N-Ac) is an anti-
oxidant scavenger of reactive oxygen species such as H2O2 that reduces free radicals in 
the cytosol to less toxic water and oxygen molecules, thus suppressing ROS function. To 
determine whether ROS were involved in VEGF-mediated p38 MAPK phosphorylation, 
HUVECs were pretreated with N-Ac, treated with VEGF for 2 or 5 min, and then p38 
MAPK serine/threonine phosphorylation was detected by immunoblotting.  VEGF 
stimulation increased p38 MAPK phosphorylation that was blocked by N-Ac (Fig. 3.4).  
However, we observed that inhibition was stronger at 2 min than at 5 min, indicating that 
ROS production occurs very rapidly and within the same timeframe of Rac1 activation. 
Tyrosine phosphorylation of adherens junction proteins is required for their ability 
to disrupt physical contacts with neighboring cells266,267.  For example, tyrosine 
phosphorylation of VE-cadherin downstream of VEGF signaling results in  
VE-cadherin clathrin and β-arrestin2-dependent internalization, thus removing it from the 
cell surface to relieve cell-cell adhesion115.   We thus investigated whether tyrosine 
phosphorylation of VE-cadherin and β-catenin after VEGF stimulation is regulated by 
ROS production.  We found that, within 2 min, VEGF increased phosphorylation of both 
VE-cadherin and β-catenin, whereas phosphorylation was not detected in unstimulated 
cells (Fig. 3.5).  Moreover, pretreatment of HUVECs with N-Ac inhibited tyrosine 
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phosphorylation of VE-cadherin, and partially inhibited β-catenin phosphorylation. N-Ac 
treatment alone did not affect VE-cadherin, but lowered β-catenin phosphorylation below 
basal levels. 
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Figure 3.4 N-Ac reduces VEGF-induced p38 MAPK phosphorylation. 
HUVECs were pretreated with 5 mM N-Ac for 14 h at 37°C, starved for 1 h, and then 
VEGF was added for 2 min or 5 min.  The upper panel shows phosphorylated β-catenin 
after VEGF treatment in the absence or presence of N-Ac. The lower left panel shows 
total levels of β-catenin expression. Blots are representative of at least three independent 
experiments. 
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Figure 3.5 Effects of VEGF and N-Ac on β-catenin and VE-cadherin tyrosine 
phosphorylation. 
HUVECs were pretreated with either 5 μM N-Ac for 14 h at 37°C. Cells were then serum 
starved for 1 h, and treated with 10 ng/mL VEGF for 2 min.  Lysates were then 
immunoprecipitated for β-catenin or VE-cadherin as described in Materials and Methods.  
Phosphorylated β-catenin and VE-cadherin was detected by western blotting using a 
phospho-epitope-specific antibody. The upper panel shows that N-Ac prevents tyrosine 
phosphorylation.  The middle panel shows equal protein levels in every 
immunoprecipitation, whereas the lower panel shows equal protein loading in cell 
lysates.   
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VE-cadherin is tyrosine phosphorylated on two critical residues in response to VEGF – 
There are nine tyrosine residues in the C-terminal tail of VE-cadherin. However, tyrosine 
phosphorylation of VE-cadherin on two key residues (Tyr658 and Tyr731) prevents 
binding of associating proteins p120catenin and β-catenin, respectively122.  Since 
p120catenin has been shown to retain VE-cadherin on the cell surface and β-catenin 
helps link VE-cadherin to the actin cytoskeleton, the inability of these proteins to bind 
VE-cadherin provides a mechanism for adherens junction disassembly.  To determine if 
these residues are tyrosine phosphorylated after VEGF stimulation, serum-starved 
HUVECs were treated in the presence of VEGF for 20 min. VE-cadherin was 
phosphorylated on residue Tyr658 in response to VEGF that occurred from 2-10 min.  
Similarly, Tyr731 displayed an increase in phosphorylation; however, phosphorylation 
was observed from 2-5 min (Fig. 3.6).  When we observed tyrosine phosphorylation of 
these residues, particularly Tyr731 that regulates β-catenin binding, we wanted to 
investigate if this phosphorylation event was mediated downstream of ROS.  To inhibit 
ROS production, cells were pretreated with N-Ac then stimulated cells with VEGF for 2 
or 5 min.  We found that N-Ac prevented VEGF-induced phosphorylation of Tyr731 at 
both timepoints (Fig. 3.7).  Interestingly, the N-Ac inhibition was stronger at 5 min, 
suggesting that phosphorylation that occurs at this time may be highly influenced by ROS 
production. 
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Figure 3.6  Distinct tyrosine residues of VE-cadherin are phosphorylated after 
VEGF stimulation.   
HUVECs were serum starved for 1 h and treated with 10 ng/mL VEGF for the specified 
times and immunoblotted for tyrosine 658 and tyrosine 731 of VE-cadherin as described 
in Materials and Methods. Phosphorylation of VE-cadherin on either Tyr658 or Tyr31 
was analyzed by western blotting using a phospho-epitope-specific antibody. The upper 
panels show phosphorylation on specific residues of VE-cadherin after VEGF treatment. 
The lower panels show total VE-cadherin expression. The histograms on the right show 
quantification of the fold increase in VE-cadherin phosphorylation after VEGF 
stimulation in three independent experiments (n=3).  
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Figure 3.7 N-Ac treatment decreases VE-cadherin Tyr731 phosphorylation. 
HUVECs were pretreated with 5 mM N-Ac for 14 h at 37°C, starved for 1 h, and then 
VEGF was added for 2 min or 5 min.  The upper panel shows phosphorylated VE-
cadherin after VEGF treatment in the absence or presence of N-Ac. The lower left panel 
shows total levels of VE-cadherin Tyr731 expression. Blot are representative of three 
independent experiments. 
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DISCUSSION 
 
VEGF signaling to adherens junction proteins such as VE-cadherin and β-catenin 
regulates cell-cell barrier function. Both in vivo and in vitro studies have shown that 
VEGF decreases barrier function through the uncoupling of VE-cadherin-mediated 
adhesions28,115  This uncoupling is a result of VEGF-mediated phosphorylation of VE-
cadherin, which leads to its internalization and/or and dissociation from the cytoskeleton.  
Here, we test a possible mechanism for adherens junction disassembly in response to 
VEGF.  Our previous work (discussed in Chapter 2) showed that VEGF induces an early 
(~ 5 min) and late (~30 min) biphasic activation of Rac1.  Although we focused on Rac1 
activity at the later timepoint in our preceding work, we decided to investigate the earlier 
Rac1 activation and its possible influence on vascular permeability.  We demonstrate that 
VEGF induces a rapid and transient increase in Rac1 activity at 1 min, which is in 
agreement with data published by Zeng and colleagues26.  As the data stand, it is 
unknown whether VEGF-induced Rac1 activation causes an increase in ROS production 
and subsequent phosphorylation of proteins at adherens junctions.  Our future work will 
address these unanswered questions.   
The addition of ROS such as H2O2 to endothelial cells causes a rapid and 
significant loss of cadherin/catenin-mediated contacts276.    A member of the MAPK 
superfamily, p38 MAPK is activated when cells are stressed such as by oxidative stress 
due to increased ROS277. Work by Rousseau et al. (1997) demonstrated that VEGF 
promoted p38 MAPK phosphorylation143. That same year, another group used  
phosphorylation of p38 MAPK as an indicator of increased cellular response to  
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ROS29,278.  Since that time, p38 MAPK phosphorylation has been used as a readout of 
ROS production279. We used this method to determine if VEGF caused an increase in 
ROS synthesis.  We observed an increase in p38 MAPK phosphorylation in response to 
VEGF, which occurs up to 10 min then declines. Another study observed similar results 
using dichlorofluorescein (DCF), a fluorescent dye that detects ROS.  This group noted 
an increase in ROS production that was highest at 20 min and was inhibited by dominant 
negative Rac1, implying that VEGF-mediated ROS production occurred downstream of 
Rac1 activity177.  The discrepancy in length of p38 MAPK phosphorylation between the 
two studies may be due to different VEGF concentrations and endothelial cell types. We 
continued our study by showing that scavenging ROS with N-Ac blocks VEGF-induced 
p38 MAPK phosphorylation with a stronger effect seen at 2 min versus 5 min. These data 
suggest that p38 phosphorylation after VEGF stimulation is downstream of ROS, but the 
reason for stronger inhibition at 2 min needs further investigation.  To date, parallel 
studies to correlate DCF fluorescence and p38 MAPK phosphorylation with ROS 
production have not been published.   
VEGF has been highly studied for its effects on proteins at adherens junctions.  
VEGF signaling regulates the phosphorylation state of VE-cadherin and its associating 
protein (β-catenin, p120-catenin, and γ-catenin) 28,120,170,259,266. Previous studies have 
shown that VEGF phosphorylates VE-cadherin and β-catenin 15-60 min after stimulation 
with a peak around 30 min170,266. However, we wanted to determine if these proteins were 
phosphorylated in response to VEGF at 2 min, an earlier timepoint that was consistent in 
our studies.  We observed that VEGF phosphorylates both VE-cadherin and β-catenin at 
2 min. The VE-cadherin data is in agreement with Lambeng et al. (2005) who saw a 
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similar result in HUVECs120. More importantly, we concluded that VEGF-induced VE-
cadherin phosphorylation was inhibited by N-Ac, and β-catenin was inhibited to a lesser 
extent. These data imply that VE-cadherin is a more direct target of ROS activity than β-
catenin; however, it is difficult to determine which protein is targeted by ROS first.   
The C-terminus of VE-cadherin has nine distinct tyrosine residues. Of these nine 
residues, Tyr658 and Tyr731 were found to be necessary for endothelial barrier function.  
Tyr658 binds p120catenin, whereas Tyr731 binds β-catenin. Phosphomimetic (tyrosine to 
glutamic acid) mutations of these residues resulted in decreased barrier function and were 
unable to bind p120catenin and β-catenin. Despite these defects, VE-cadherin remained 
expressed on the cell surface, suggesting that neither residue promoted VE-cadherin 
endocytosis122.  We sought to find out whether VEGF stimulation leads to 
phosphorylation these residues. Using phosphospecific antibodies, we determined that 
VEGF stimulation of HUVECs results in phosphorylation both Tyr658 and Tyr731.  
Phosphorylation of Tyr658 was elevated 2-10 min after VEGF stimulation, whereas 
Tyr731 was phosphorylated 2-5 min after VEGF treatment. We also found that N-Ac 
prevented VEGF-induced phosphorylation of Tyr731 at both 2 and 5 min with a stronger 
inhibition seen at 5 min.  This data suggests that VEGF signaling regulates these two 
residues and binding of β-catenin to VE-cadherin is regulated by ROS.  Src family 
kinases have been shown to mediate dissociation of VE-cadherin-mediated adhesion7,259.  
Phosphorylation of Tyr658 and Tyr731 was shown to be Src-dependent122.  Other VE-
cadherin residues have been implicated in mediating its function.  A study by Wallez and 
colleagues showed that another tyrosine residue within the C-terminus of VE-cadherin, 
namely Tyr685, was phosphorylated in response to VEGF in a Src-dependent manner and 
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was required for VEGF-induced endothelial cell migration.  However, VEGF stimulation 
did not affect phosphorylation of Tyr658 or Ty731 in this study121.  The reason for the 
difference with the current study is not clear. In addition, VEGF stimulation leads to 
phosphorylation of serine 665 (Ser665) in a signaling pathway that required both Src and 
Rac1 effector p21-activated kinase (PAK).  Phosphorylation of Ser665 leads to VE-
cadherin endocytosis, and ultimately,  vascular permeability115.   These studies suggest 
that multiple residues on VE-cadherin mediate its function, but these residues must be 
strictly regulated to ensure the proper outcome.  
Together, our data provides preliminary results for a very interesting mechanism 
that couples VEGF signaling to adherens junction regulation via ROS. Several studies 
mentioned in this discussion have separately addressed how VEGF signaling may cause 
tyrosine phosphorylation and vascular permeability by adherens junction proteins. Our 
hypothesis offers a direct and testable pathway that links VEGF to VE-cadherin and β-
catenin tyrosine phosphorylation through Rac1 and ROS. Although, many unanswered 
questions require further investigation, our current data suggest the following model 
illustrated in Figure 3.8. 
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Figure 3.8  Proposed model of VEGF signaling via ROS to induce endothelial cell 
permeability.  
This model proposes the hypothetical pathway activating the production of reactive 
oxygen species (ROS) downstream of VEGFR-2 signaling to promote endothelial cell 
permeability. Activation of Rac1 by VEGFR-2 leads to an increase in ROS production. 
p38 MAP kinase is phosphorylated as a  result of ROS production.  Alternatively, 
phosphorylation inactivates protein tyrosine phosphatases, which in turn, causes an 
increase in tyrosine kinase activity.  This kinase activity mediates phosphorylation of VE-
cadherin, β-catenin and other adherens junctions proteins to promote endothelial cell 
disassembly. 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
CHAPTER FOUR 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
VEGF is an important signaling molecule in endothelial cell behavior and 
function during embryogenesis and the maintenance of adult tissues. Dysregulated VEGF 
signaling has been implicated in tumor angiogenesis, ischemic stroke, and a number of 
other vascular diseases, but the pathways downstream of VEGF signaling remain 
incompletely defined.  Historically, our lab has studied the role of Rho GTPases in cell 
morphology and function. Our lab has also characterized the effects of Vav2 exchange 
activity downstream of EGF and PDGF signaling, cell migration, and cadherin-regulated 
junction formation213,233,280. In this dissertation, I focused on how VEGF regulates Rac1 
activity and subsequent endothelial cell behavior.  These studies have led to the 
conclusion that VEGF signals to Rac1 through exchange factor Vav2 in a VEGFR-2- and 
Src-dependent manner during endothelial cell migration.  In addition, I have provided 
preliminary evidence that VEGF stimulates vascular permeability by promoting the 
tyrosine phosphorylation of VE-cadherin and β-catenin downstream of ROS production. 
 
 
 
 
 141
SUMMARY 
The major findings of this dissertation are as follows: 
1. VEGF induces biphasic activation of Rac1 in endothelial cells with an early (~1-5 
min) and late (~30 min) periods of activation. 
2. The late activation of Rac1 is not observed with RhoA or Cdc42. 
3. Exchange factor Vav2 couples VEGF signaling to Rac1 downstream of VEGFR-2 
signaling. 
4. Vav2 is tyrosine phosphorylated upon VEGFR-2 signaling and Src kinase 
activity. 
5. Vav2 is phosphorylated on tyrosine 172 in response to VEGF in a Src-dependent 
manner, implying that Src may regulate relieving autoinhibition of Vav2 required 
for exchange activity.  
6. Src mediates VEGF-induced Rac1 activation. 
7. Vav2 is necessary for VEGF-induced cell migration and wound healing. 
8. VEGF induces tyrosine phosphorylation of VE-cadherin and β-catenin in a ROS-
dependent manner. 
9. VEGF stimulates phosphorylation of tyrosine 658 and tyrosine 731 on VE-
cadherin. 
10. Inhibition of ROS with N-Ac perturbs tyrosine 731 phosphorylation on VE-
cadherin, suggesting that redox signaling mediates binding of β-catenin to VE-
cadherin. 
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Role of Vav2 in Vascular Biology and Physiology 
In Chapter 2, we investigated the molecular mechanisms that couple VEGF 
signaling to Rac1 during endothelial cell migration.  Our data concluded that VEGF acts 
through exchange factor Vav2 to activate Rac1; in addition, Vav2 exchange activity is 
regulated by VEGFR-2 signaling and Src kinase activity.  Moreover, silencing Vav2 
expression with siRNA perturbs VEGF-induced chemotaxis and wound healing.  
However, there are several unanswered questions that could provide further 
understanding of Vav2 regulation in this signaling pathway.   In a previous study, Vav2 
was shown to directly bind the cytoplasmic tail of EGFR228.  We showed that Vav2 is 
activated downstream of VEGFR-2 signaling, but we then wanted to determine whether 
Vav2 could directly bind the receptor in order to become tyrosine phosphorylated.  To 
determine whether Vav2 directly associated with VEGFR-2, HUVECs were treated with 
VEGF, cells then were immunoprecitated for Vav2 or VEGFR-2, and immunoblotted for 
VEGFR-2 or Vav2.  We did not detect Vav2 co-immunoprecipitating with VEGFR-2; 
however, we found that Vav2 was tyrosine phosphorylated as seen with our previous data 
(Fig. 4.1A and B).  As a positive control, we immunoblotted for Src in the VEGFR-2 
immunoprecipitates and observed that Src associates with VEGFR-2 after 5 min VEGF 
stimulation (Fig. 4.1B) This data suggest that one or more adaptor proteins may localize 
Vav2 in close proximity to the receptor.  We hypothesized that the adaptor protein Shc 
may help bring Vav2 close to the receptor or kinases for tyrosine phosphorylation. Shc is 
a SH2 domain-containing protein that exists in three isoforms (p46, p53, and p66) and 
connects activated cell-surface receptor signaling to intracellular signaling molecules.  
Multiple studies implicated Shc acting in response to VEGF receptor signaling.  Zanetti 
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et al. (2002) showed that Shc binds the cytoplasmic tail of VE-cadherin downstream of 
VEGFR-2 signaling and promotes its dephosphorylation by PTPs231.  Shc has been 
shown to bind the C-terminus of VEGFR-3, but to date, has not been shown to bind 
VEGFR-2281.  However, a related Shc protein, Shb, was shown by Holmqvist and 
colleagues to bind a C-terminal tyrosine residue on VEGFR-2 and mediate VEGF-
dependent cell migration75.  Recently, it was found that another adaptor protein Gab1 
might also link VEGFR-2 to Vav2. Gab1 is a SH3 domain-containing protein that recruits 
PI3K, SHP-2 and other effector proteins in response to activation by upstream receptors, 
such as EGFR. In addition, Gab1 has been shown to associate with VEGFR-2 and Shc in 
endothelial cells; in addition, overexpression of Gab1 upregulates endothelial cell 
migration and subsequent tube formation282. These adaptor proteins might act as a bridge 
that links VEGFR-2 to Vav2 for tyrosine phosphorylation. Further studies are required to 
determine how these proteins may bring Vav2 close to the receptor or mediate Src-
dependent phosphorylation. 
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Figure 4.1  Vav2 does not directly associate with VEGFR-2. 
(A) Serum-starved HUVECs were stimulated with 10 ng/mL VEGF, endogenous Vav2 
immunoprecipitated, and then probed for VEGFR-2, Vav2,or phosphotyrosine. VEGFR-2 
did not immunoprecipitate with Vav2 (upper panel), but Vav2 was tyrosine 
phosphorylated after 30 min of stimulation (first middle panel). The second middle panel 
shows equal Vav2 levels in every immunoprecipitation, whereas the lower panel shows 
equal Vav2 loading in cell lysates. Blots are representative of four independent 
experiments.  (B) HUVECs were serum starved and treated with 10 ng/mL VEGF for 30 
min or 5 min VEGFR-2 was immunoprecipitated, and then probed for Vav2, VEGFR-2,  
or Src. VEGFR-2 did not immunoprecipitate with Vav2 (upper panel). The second 
middle panel shows equal VEGFR-2 levels in each immunoprecipitation, whereas the 
lower panel shows equal VEGFR-2 loading in cell lysates. The bottom panel shows that 
Src was immunoprecipitated with VEGFR-2. Blots are representative of three 
independent experiments. 
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Our data revealed that Src regulates tyrosine phosphorylation of Vav2 in response 
to VEGF. However, one of the unanswered questions regarding Vav2 is which member 
of the Src family of kinases (SFK) regulates its tyrosine phosphorylation.  In immune 
cells, Vav2 is phosphorylated by Syk, Fyn, and Lck, members of the Src family kinases 
that link receptor signaling to Rho GTPases283.  Another study has addressed if Src 
mediates Vav2 phosphorylation using SFK pharmacological inhibitors, siRNA against 
Src, as well as dominant negative and active Src constructs. Consistent with our results, 
these techniques illustrated that Vav2 is tyrosine phosphorylated by Src after VEGF 
stimulation115.  Src family members Lyn and Fyn have also been detected in endothelial 
cells, but particularly localized in brain284,285.  Interestingly, C-terminal Src kinase (Csk), 
which negatively regulates the of activity of Src and related kinases, is required for 
angiogenic sprouting, vessel remodeling, and brain development286,287.  Although these 
studies have not fully defined which Src family member phosphorylates Vav2 in 
endothelial cells, this question can addressed with the use of wild-type and mutant SFK 
constructs.  These studies would indicate that Src kinases can positively, or negatively, 
regulate Vav2 tyrosine phosphorylation and Rac1 activation. 
Vav2 is targeted to the plasma membrane as another means of regulating its 
exchange activity.  Membrane translocation to PIP2 and PIP3 (products of PI3K) places 
Vav2 in proximity with upstream regulators and downstream effectors for activation.   
Vav2 undergoes this translocation in response to EGF and PDGF, but it remains 
unknown whether VEGF can cause a similar effect214,234. We theorize that after VEGF  
stimulation phosphorylated Vav2 is recruited to the membrane where it can interact with 
Rac1 and proteins such as WAVEs.  These interactions might lead to lamellipodia 
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formation that is required for cell migration.  To test this theory, we could perform 
subcellular fractionation to differentiate membrane-bound versus cytoplasmic pools of 
Vav2 after VEGF stimulation.  In addition, PI3K inhibitors wortmannin and LY294002 
could be used to perturb the formation of PIP3 substrates, and then determine if this 
inhibition prevents Vav2 targeting.  Lastly, adenoviral or lentiviral Vav2 constructs 
tagged with green fluorescent protein (GFP) would help address this theory.  If Vav2 is 
translocated to discrete areas of the plasma membrane after VEGF stimulation, its 
recruitment could be visualized by immunofluorescence, especially if co-stained for the 
leading edge marker cortactin.  These collective experiments would elucidate if 
membrane targeting of Vav2 is necessary for its exchange activity downstream of VEGF. 
 Until recently, the role of Vav2 in cardiovascular physiology had not been 
explored. Genetic deletion of Vav2 was shown to cause defects in T- and B-cell function, 
but a phenotype was not observed in the vascular system194-196.  A recent study from Xose 
Bustelo’s laboratory investigated the role of Vav2 in cardiovascular homeostasis.  Using 
Vav2 knockout mice, they demonstrated that loss of Vav2 caused hypertension, 
tachycardia, arterial remodeling defects, and renal dysfunction206.Of note, similar results 
were observed in a previous study that focused on Vav3205.  To test our hypothesis using 
an animal model, we would like to isolate endothelial cells from Vav2-/- mice and 
determine if these cells display the same phenotype seen in our in vitro studies.  In 
particular, we would like to use these knockout cells for migration and tube formation 
experiments.  We would perform rescue experiments by infecting cells with human Vav2 
using adenoviral or lentiviral constructs and treating the cells with VEGF. These 
experiments would determine if Vav2 is necessary and sufficient to mediate VEGF-
 148
induced endothelial cell migration.  If not, Vav3 might play a redundant role in VEGF-
induced migration, though our data suggest this alternative is unlikely. 
 
Role of ROS in VEGF-induced Vascular Permeability 
 As described in Chapter 3, we sought to elucidate if VEGF activates Rac1, which 
in turn promotes ROS generation by NADPH oxidase complex to weaken adherens 
junctions.  Our data suggested that VEGF induces tyrosine phosphorylation of VE-
cadherin downstream of redox signaling.  In addition, VEGF promotes phosphorylation 
of Tyr658 and Tyr731 on VE-cadherin.  These tyrosines are in the binding sites for 
p120catenin and β-catenin, respectively.  Lastly, inhibiting ROS production markedly 
reduces VEGF-induced Tyr713 phosphorylation, implying that ROS control binding of 
β-catenin to VE-cadherin.  However, our preliminary study did not fully investigate the 
signaling pathway that results in ROS production.  Studies have shown that VEGF 
upregulates ROS production in endothelial cells, especially downstream of Rac1 
activation153,176,271.  We could extend these studies by infecting wild-type or dominant 
negative Rac1 (N17Rac1) in endothelial cells and do a parallel study of VEGF-induced 
ROS production.  In this parallel study, we would infect cells with either wild-type Rac1 
or N17Rac1 and treat with VEGF. Next, we would either detect ROS production with 
dichlorofluorescein (DCF), a fluorescent dye that detects free radicals, or detect p38 
MAPK phosphorylation by immunoblotting.  These experiments would allow us to 
determine if VEGF upregulates ROS production in our system and if p38 MAPK 
phosphorylation is an effective readout of p38 MAPK production. 
 Another unanswered question in this model is, if VEGF leads to Rac1 activation, 
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which upstream exchange factor is regulating this effect?   Our previous studies suggest 
that Vav2 couples VEGF signaling to Rac1, but this was studied in the context of 
endothelial cell migration.  Nonetheless, Vav2 might activate Rac1 in response to VEGF 
during vascular permeability.  In neutrophils, Vav1 activates Rac1 and increases p67phox 
(a NADPH oxidase component) production of ROS in response to fMLP, a synthetic 
peptide that mimics bacterically-derived proteins 288.  However, another study showed 
that EGF stimulation causes increased ROS production in a mechanism that involves both 
the Rac GEF β-Pix and Rac1.  In this study, Vav1 and Vav2 were tested for their effect 
on H2O2 production, but neither protein produced significant stimulation289.  To 
determine if Vav2 is involved in VEGF-induced ROS production, we would infect 
HUVECs with GFP-tagged wild-type and constitutively active Vav2 and stimulate cells 
in the absence or presence of VEGF.  Then, we would monitor the ROS generation by 
analyzing DCF fluorescence.  If we did not observe a marked change in ROS production 
with Vav2, then we would focus on another exchange factor such as β-PIX.  Based on 
these data, the next logical question is, how does VEGF affect the NADPH oxidase 
complex?  Although we did not address this question in our preliminary work, findings 
from several groups have previously characterized this complex.  A recent review nicely 
combines these findings and details how VEGF signals through the NADPH oxidase 
complex with an emphasis on each component290. 
 ROS inactivates protein tyrosine phosphatases (PTPs) by oxidizing a critical 
cysteine residue in their active sites, which leads to a net increase in phosphorylation by 
tyrosine kinases27.   This mechanism could lead to an increase in tyrosine 
phosphorylation of adherens junction proteins such as the VE-cadherin-β-catenin 
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complex. Phosphorylation of this complex may ultimately lead to a loss of cell-cell 
adhesion.  Our findings showed that both VE-cadherin and β-catenin are tyrosine 
phosphorylated after VEGF stimulation. When cells were treated with the ROS scavenger 
N-Ac, phosphorylation of VE-cadherin was markedly decreased compared to β-catenin.  
This decrease was also observed with VEGF-mediated Tyr731 phosphorylation on VE-
cadherin when treated with N-Ac. Regarding these data, it is unknown which PTPs or 
tyrosine kinases are mediating the phosphorylation of these proteins.   It is unlikely that 
only one PTP or tyrosine kinase is regulating this mechanism.  A few of the tyrosine 
phosphatases that have been shown to influence VE-cadherin function are SHP-2, DEP-1, 
and VE-PTP123,182,189.  Of these PTPs, SHP-2 is a strong candidate for regulating this 
pathway.  SHP-2 is a target of ROS, regulates VEGFR-2 signaling, and is found near VE-
cadherin182,185,188.  DEP-1 localizes to the VE-cadherin-β-catenin complex of confluent 
monolayers after VEGF signaling.  This localization allows DEP-1 to dephosphorylate 
the VE-cadherin-β-catenin complex, thus strengthening cell-cell adhesions and 
promoting contact inhibition123.  Although DEP-1 has not been shown to be a target of 
ROS, DEP-1 is a reasonable choice for this pathway because it is influenced by VEGFR-
2 signaling and localizes at adherens junctions.  Although VE-PTP has been shown to 
associate with and dephosphorylate VE-cadherin, it is not activated by VEGF184,189. To 
determine whether these PTPs are inactivated upon VEGF-induced ROS production, we 
would use an antibody that recognizes the oxidized, inactive form of specific PTPs. 
Alternatively, we could use a procedure called a biotin switch assay that labels oxidized 
or modified thiol groups on cysteines in the catalytic domain of PTPs with biotin and 
precipitates inactive PTP with strepavidin beads. Although ROS can inactivate PTPs, it is 
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unknown if ROS can directly activate tyrosine kinases.  Yet, it is suggested that Src and 
Pyk2 may regulate the net increase in phosphorylation due to kinase activity. As it 
pertains to Src, our results (discussed in Chapter 2) are consistent with studies that show 
VEGF activates Src115.  In addition, Src tyrosine phosphorylates p47phox, a component of 
the NADPH oxidase complex, to promote Rac1 activation in endothelial cells291.  Pyk2 
has been shown to tyrosine phosphorylate β-catenin after its dissociation from VE-
cadherin after ROS generation30. Despite this result, biochemical experiments would need 
to be performed after VEGF treatment to determine if Src or Pyk2 phosphorylates VE-
cadherin or β-catenin under the same conditions. These two kinases are molecules that 
potentially phosphorylate VE-cadherin and β-catenin in response to VEGF in a ROS-
dependent manner.   
 One final consideration deals with the effects of VEGF on vascular permeability 
in vitro. Even though VEGF was first characterized as a permeability factor, these studies 
were performed in vivo mouse models that more closely mimic pathological situations.   
VEGF has been shown to decrease endothelial barrier function in vivo; however, 
duplicating VEGF-induced permeability in vitro may not result in significant 
effects169,292.  We performed numerous experiments treating confluent endothelial cells 
with varying concentrations of VEGF to mimic permeability effects seen in vivo.  We 
analyzed any change in permeability using a system that measures the electrical 
impedance across a cell monolayer on a continuous real-time scale.  We observed that 
VEGF did not have an immediate permeability effect on the cells unlike other known 
permeability agonists such as thrombin and EDTA.  In fact, we observed an increase in 
endothelial barrier function that correlated with increasing VEGF concentrations (0-
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100ng/mL) that lasted about three hours. We then compared the increasing VEGF 
concentrations with cells treated with N-Ac or H2O2 in the presence of VEGF.  The cells 
displayed increased impedance with N-Ac treatment and decreased impedance with H2O2 
treatment as expected (data not shown).  These surprising results seem to contradict long 
established dogma about VEGF-induced permeability.  However, a few studies have 
observed similar results170,293,294.  Specifically, a study by Seebach and coworkers 
demonstrated that VEGF treatment of HUVECs results in rapid and transient increase in 
endothelial barrier function using transendothelial electrical resistance (TER) and this 
TER increase was accompanied by Rac1 activation.  Moreover, increased barrier function 
correlated with an increase in tyrosine phosphorylation of VE-cadherin and β-catenin, 
which is consistent with our data (Chapter 3)170.    In addition, though VEGF causes 
fenestrations in vivo, in many studies these fenestrations did not result in intracellular gap 
formation169,292,295.  It is possible that the increase in barrier function we observe upon 
VEGF stimulation switches vascular permeability from a paracellular route to a 
transcellular route, in which cells and small molecules transmigrate through the cell in 
vesicles.  The increase in VE-cadherin and β-catenin tyrosine phosphorylation, which 
normally represents decreased barrier function, may disorganize these proteins to slightly 
weaken junctions, yet overall favors transcellular migration. This fascinating mechanism 
provides evidence how endothelial cell junctions are tightly regulated and how migratory 
routes are determined.   
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Role of Rho GTPases in Vascular Diseases   
Rho GTPases mediate various cellular functions including cell adhesion, motility, 
contractility, proliferation, and gene expression.  All of these functions, when 
dysregulated, are involved in the pathogenesis of cardiovascular or vascular-related 
diseases.  Different cell types involved in vascular development and function such as 
endothelial cells, vascular smooth muscle cells, and cardiomyocytes undergo changes that 
involve Rho GTPases.  Aberrant activation of Rho GTPase signaling pathways can lead 
to hypertension, atherosclerosis, and diabetes.  We will focus on the role of Rac1 in the 
etiology of the three major vascular diseases mentioned above.  Moreover, we will 
discuss the potential molecular mechanisms underlying these pathologies based on our 
data.  In addition to this discussion, a table of Rho GTPases and their associated vascular 
pathologies are described in Table 4.1. 
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TABLE 4.1 Rho GTPases and Vascular Pathologies 
 
GTPase 
 
     Pathology 
Cells 
Affected 
Signaling 
Pathway 
Aberrant Cell 
Process 
 
Refs 
 
 
 
 
 
 
 
RhoA 
 
Atherosclerosis 
 
 
 
Cerebral Edema 
 
Hypertension 
 
 
Thrombosis 
 
 
Restenosis 
 
VSMC              
VSMC              
EC 
  
Arterial 
 
Renal SMC 
VSMC 
 
Platelets 
 
 
Arterial SMC 
 
 
Elastin 
PDGF 
Thrombin 
  
ET-1 
 
Ang II 
Insulin 
 
Thrombin 
Thromboxane 
 
Redox 
 
Vasoconstriction 
Cell Proliferation 
Barrier Function 
 
Vasoconstriction 
 
Vasoconstriction 
Remodeling 
 
Platelet 
Aggregation 
 
Migration 
 
 
 
296-298 
 
 
299 
 
300,301 
 
 
302 
 
303 
 
 
 
 
 
 
 
 
Rac1 
 
 
Hypertension 
 
 
Atherosclerosis 
 
 
 
 
Diabetes Mellitus 
 
  
Ischemia/ 
Reperfusion 
Injury 
 
 
 
Arterial             
Arterial 
 
Coronary 
Arterial 
EC 
 
 
Carotid 
Arterial EC 
 
Cardiac 
 
 
 
 
Redox 
ET-1 
 
ICAM/VCAM 
Growth Factor/ 
Cytokine 
 
 
Redox 
 
 
AngII 
 
 
Vasoconstriction 
EC Dysfunction 
 
Barrier Function 
TEM 
 
 
 
EC Dysfunction 
 
 
Cardioprotection 
 
 
304-306 
 
262,307 
 
 
 
308 
 
 
309 
 
 
 
 
 
Cdc42 
 
Ischemia/ 
Reperfusion 
Injury 
 
Warner’s 
Syndrome 
(Premature 
Atherosclerosis) 
 
Atherosclerosis 
 
 
Hippocampal 
 
 
 
Stromal 
 
 
 
Macrophages 
EC 
 
 
Redox 
 
 
 
Apo 
 
 
 
PAF 
GMFG 
 
Cell Survival 
 
 
 
Lipid Metabolism 
 
 
 
Cell Elongation 
Cell Migration 
 
129 
 
 
310 
 
 
 
311,312 
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Table 4.1  Rho GTPases and Vascular Pathologies 
This table highlights how Rho proteins have been implicated in vascular disease.  This 
table includes the specific pathology, cells affected, signaling pathway involved, and the 
resulting aberrant cellular process caused by dysregulated Rho activity. 
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Hypertension 
Hypertension (also known as high blood pressure) is a medical condition in which 
blood pressure is constantly elevated.  In other words, a high amount of force is needed to 
circulate blood through blood vessels.   This condition is characterized by endothelial cell 
dysfunction and abnormal vascular remodeling. Chronic hypertension is associated with 
increased risk of stroke, heart attack, heart disease, and renal failure.  According to the 
latest statistics from the American Heart Association (taken in 2004), over 70 million 
people were estimated to have hypertension, and for 50 million people, hypertension may 
have contributed to death313.  A number of external factors implicated in the development 
of hypertension including environment and salt intake can be controlled to decrease risk.  
However, many other biological factors such as renin production, insulin resistance, and 
genetics intrinsically cause this condition.  A deeper understanding of the molecular 
mechanisms involved in hypertension might help develop new therapeutics to treat or 
prevent this condition. 
In the past five years, Rac1 has been shown to contribute to hypertension.  
Specifically, dysregulated Rac1 signaling can cause an increase in NADPH oxidase 
activity, and subsequently elevate arterial blood pressure.  Li and colleagues showed that 
dominant negative Rac1 suppressed levels of superoxide (O2-) production in a arterial 
hypertensive rat model304. Transgenic overexpression of constitutively active Rac1 has 
been shown to cause hypertension and left ventricular hypertrophy due to blood pressure 
overload,  which was inhibited by the ROS scavenger N-Ac306.  A study by Wojciak-
Stothard et al. (2006) demonstrated that downregulated Rac1 activity contributes to 
pulmonary hypertension (PH), a hypoxia-driven condition characterized by aberrant 
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pulmonary remodeling in newborns. In pulmonary hypertensive (PH) pigs, this group 
showed that Rac1 activity is markedly reduced and this decrease correlated with a 
decrease in ROS and VEGF production in vivo314. In addition, this model showed a Rac1-
dependent increase in endothelial barrier function. In this case, the protective barrier 
effect of Rac1 prevents vascular leakage, which in turn may increase pressure in 
pulmonary arteries.  Together, these studies indicated that Rac1 plays a role in 
mechanisms that lead to hypertension, but the mechanisms may be different depending 
on the disease etiology.  Our data showed that VEGF-induced ROS production may 
regulate endothelial barrier function (Chapter3). Changes in endothelial barrier function, 
particularly through adherens junctions, have been associated with vascular 
remodeling315.  It is possible that Rac activation is perturbed in response to upstream 
stimuli such as VEGF, which results in aberrant vascular remodeling and subsequently 
hypertension.  Moreover, it would be interesting to look at the role of Rac GEFs such as 
Vav2 in this signaling pathway because it has been shown that Vav2 knockout mice are 
hypertensive206. 
Atherosclerosis 
Atherosclerosis is a chronic inflammatory disease characterized by the deposition 
of lipids (e.g., cholesterol and triglycerides) in the walls of arteries. This disease is 
initiated by the formation of lesions that develop into hard, lipid-containing plaques 
under the endothelium called fatty streaks. These plaques cause damage to the blood 
vessel wall and stimulate an inflammatory response that recruits leukocytes to the site of 
insult.  Leukocyte adhesion is promoted by redox signaling in activated endothelial cells, 
which upregulates adhesion molecules that facilitate leukocyte binding.  Hypertension is 
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a known risk factor for atherosclerosis because it may activate damaged endothelial cells 
and promote ROS-stimulated adhesion molecule expression.   It was previously shown 
that endothelin-1 (ET-1) stimulates vascular cell adhesion molecule (VCAM) expression 
in hypertensive rat arteries and this elevated expression is NADPH oxidase-dependent305. 
This group also showed that DN Rac1 inhibits ET-1-stimulated VCAM expression, 
which may prevent the formation of atherosclerotic plaques304.   
Activation of Rac1 is also necessary for the pathogenesis of atherosclerosis in 
endothelial cells, especially in response to shear stress and growth factors.  Shear stress, 
the hemodynamic force of blood flow, is more turbulent in branched areas of blood 
vessels compared to non-branched areas.  The turbulent blood flow in branched areas 
correlates with the formation of atherosclerotic plaques. Rac1 is activated in those areas 
and upregulates expression of intercellular adhesion molecule (ICAM) in response to 
shear stress316.  The presence of growth factors in the blood vessel milieu also affects 
Rac1 activation in atherosclerosis.  Secreted by endothelial cells, epidermal growth factor 
(EGF) is a potent activator of vascular smooth muscle cells (VSMC) that proliferate and 
migrate to the endothelium.  These smooth muscle cells form a fibrous cap that coves the 
fatty streak and solidifies into a plaque.  Activated Rac1 promotes EGF-mediated 
proliferation of VSMC317.  This study provides a mechanism downstream of growth 
factor signaling that may mimic mitogenic and migratory effects seen with endothelial 
cells in our data (Chapter 2).  How VEGF signaling though Rac1 contributes to 
atherosclerotic plaque development has not been studied, though VEGF expression is 
linked to this process290,318,319.   Our data suggest that VEGF may either promote 
migration of endothelial cells after initial damage and/or regulate adhesion molecule 
 159
expression for leukocyte recruitment in a Rac1- and ROS-dependent manner.   
Diabetes Mellitus 
 Unlike hypertension and atherosclerosis, diabetes mellitus is a metabolic disorder 
that can affect the vascular system as a secondary complication.  Diabetes mellitus, or 
simply diabetes, is characterized by high levels of glucose (hyperglycemia) in the 
bloodstream because of the inability of glucose to enter cells to provide energy.  Diabetes 
affects about 7% of the US population and occurs in three forms (Type 1, Type 2, and 
gestational diabetes), with Type 2 diabetes being most prevalent (American Diabetes 
Association website, 2007).  Although each form has different symptoms and biological 
consequences, each form is generally due to the inability to synthesize or properly use 
insulin.  Insulin is a hormone that regulates the uptake of glucose by cells.  Many cells 
use glucose as their primary source of energy; therefore, a lack of glucose causes them to 
use alternative sources for energy such as amino acids.  However, this use of alternative 
sources for energy can have adverse effects on blood chemistry that lead to death. 
 A chronic elevation of glucose can damage blood vessels, particularly capillaries 
and arteries, throughout the body.  Vascular injury causes endothelial cell dysfunction 
due to increased ROS production, resulting in oxidative stress.  Until recently, Rac1 had 
not been shown to play a role in ROS production that exacerbates the disease. The first 
study implicating Rac1 in this disease showed that its expression was decreased in 
diabetic rats, but was increased upon insulin treatment320.  However, work by Vecchione 
et al. (2006) directly correlated Rac1 activation with diabetes-associated O2- generation 
and vascular injury using a diabetic mouse model308.  This study showed that high 
glucose concentrations increased Rac1 translocation to the plasma membrane and Rac1 
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activity in this model. Elevated Rac1 levels led to increased NADPH oxidase activity and 
ROS production.  Moreover, adenoviral infection of a DN Rac1 prevented excessive 
vasoconstriction, a hallmark of diabetes308.  Studies have shown that high glucose cause 
VEGF expression in response to oxidative stress, particularly in diabetic retinopathy (the 
growth of poorly-constructed blood vessels in the retina and macula of the eye) in Type 2 
diabetes321,322. However, it is unknown how the VEGF-Rac-ROS signaling pathway is 
affected in diabetes.  Together, our data suggests a likely model that may affect 
endothelial cell dysfunction and migration in the pathogenesis of diabetes or its 
secondary vascular diseases. 
 In conclusion, VEGF signaling to Rac1 is necessary for endothelial cell behavior 
in migration that precedes vasculogenesis and angiogenesis as well as barrier function in 
vascular permeability.  This signaling pathway may be important in the development and 
progression of vascular diseases, but the mechanisms underlying these diseases require 
further investigation.   The studies described in this dissertation offer original findings of 
how VEGF, Rac1, and Rac GEFs, such as Vav2, may influence endothelial cell behavior 
in physiological and pathological states.  These data may not only elucidate their 
respective roles in blood vessel formation and function, but also provide targets for novel 
therapeutics that treat cardiovascular and vascular-associated diseases. 
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